mhtx_10q.htm

0001477932-20-002969.txt : 20200520 0001477932-20-002969.hdr.sgml : 20200520 20200520171548 ACCESSION NUMBER: 0001477932-20-002969 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20200331 FILED AS OF DATE: 20200520 DATE AS OF CHANGE: 20200520 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MANHATTAN SCIENTIFICS INC CENTRAL INDEX KEY: 0001099132 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690] IRS NUMBER: 850460639 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28411 FILM NUMBER: 20898990 BUSINESS ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-541-2405 MAIL ADDRESS: STREET 1: 244 FIFTH AVENUE STREET 2: SUITE 2341 CITY: NEW YORK STATE: NY ZIP: 10001 10-Q 1 mhtx_10q.htm FORM 10-Q mhtx_10q.htm

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal quarter ended March 31, 2020

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ____________to____________

MANHATTAN SCIENTIFICS, INC.

(Exact name of small business issuer as specified in its charter)

Delaware		000-28411		85-0460639
(State of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

244 Fifth Ave, Suite 2341

New York, New York, 10001

(Address of principal executive offices) (Zip code)

Issuer’s telephone number: (212) 541-2405

Securities registered under Section 12(b) of the Exchange Act: None

_________________________________________

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value

(Title of Class)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

There were 557,781,064 shares outstanding of registrant’s common stock, par value $0.001 per share, as of May 20, 2020.

TABLE OF CONTENTS

PART I

Item 1.	Condensed Financial Statements	3
	Condensed Consolidated Balance Sheets as of March 31, 2020 (unaudited) and December 31, 2019	3
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2020 and 2019 (unaudited)	4
	Condensed Consolidation Statements of Stockholders’ Equity for the three months ended March 31, 2020 and 2019 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2020 and 2019 (unaudited)	6
	Condensed Notes to Consolidated Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operation	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20

PART II

Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 3.	Defaults Upon Senior Securities	24
Item 4.	Mine Safety Disclosure	24
Item 5.	Other Information	24
Item 6.	Exhibits	25
SIGNATURES		26

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED BALANCE SHEETS

	March 31,			December 31,
	2020			2019
	(unaudited)
ASSETS
Current assets:
Cash	$	241,000		$	261,000
Prepaid expenses		18,000			13,000
Due from the sale of assets - current portion		300,000			300,000
Total current assets		559,000			574,000

Investment in equity securities		408,000			1,045,000
Property and equipment, net		8,000			4,000
Due from the sale of assets		600,000			600,000
Other assets		2,000			2,000
Total assets	$	1,577,000		$	2,225,000

LIABILITIES
Current liabilities:
Accounts payable and accrued expenses	$	1,504,000		$	1,510,250
Accrued expenses — related parties		667,000			583,750
Total current liabilities		2,171,000			2,094,000

Long-term liabilities:
Notes payable, net of discounts		85,000			78,000
Total long-term liabilities		85,000			78,000
Total liabilities		2,256,000			2,172,000

Commitments and Contingencies - Note 7

Series D convertible preferred, authorized 105,761 shares, 105,761 and 105,761 shares issued and outstanding, respectively		1,058,000			1,058,000

STOCKHOLDERS’ DEFICIT
Capital stock $.001 par value
Preferred, authorized 447,804 shares, 0 and 0 shares issued, and outstanding, respectively		-			-
Class A Convertible Preferred, authorized 182,525, 0 and 0 shares issued and outstanding, respectively		-			-
Class B Convertible Preferred, authorized 250,000, 49,999 and 49,999 shares issued and outstanding, respectively		-			-
Class C Redeemable Convertible Preferred, authorized 14,000, 0 and 0 shares issued and outstanding, respectively		-			-
Common, authorized 950,000,000 shares, 557,781,064 and 557,781,064 shares issued, and outstanding, respectively		558,000			558,000
Additional paid-in-capital		67,632,000			67,632,000
Accumulated deficit		(69,927,000	)		(69,195,000	)
Total stockholders' deficit		(1,737,000	)		(1,005,000	)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIT	$	1,577,000		$	2,225,000

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	THREE MONTHS ENDED
	MARCH 31,
	2020			2019

Revenue	$	-		$	-

Operating costs:
General and administrative expenses		169,000			220,000
Research and development		3,000			1,000

Total operating costs and expenses		172,000			221,000

Loss from operations before other income and expenses		(172,000	)		(221,000	)

Other income and (expenses):
Loss on fair value adjustment of investments		(553,000	)		(215,000	)
Interest expense		(7,000	)		-
Total other income (expense)		(560,000	)		(215,000	)

NET LOSS	$	(732,000	)	$	(436,000	)

LOSS PER COMMON SHARE:

Weighted average number of common shares outstanding (Basic)		557,781,064			533,781,064

Basic loss per common share	$	(0.00	)	$	(0.00	)

Weighted average number of common shares outstanding (Diluted)		557,781,064			533,781,064

Diluted loss per common share	$	(0.00	)	$	(0.00	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

For the Three Months Ended March 31, 2020

(unaudited)

Preferred Stock

$0.001 Par Value

Common Stock

Additional

Total

Series B

$0.001 Par Value

Paid-In

Accumulated

Shareholders'

Shares

Amount

Shares

Amount

Capital

Deficit

Balance

December 31, 2019

49,999

557,781,064

558,000

67,632,000

(69,195,000

)

(1,005,000

)

Net Loss

(732,000

)

(732,000

)

Blance

March 31, 2020

49,999

557,781,064

558,000

67,632,000

(69,927,000

)

(1,737,000

)

For the Three Months Ended March 31, 2019

(unaudited)

Preferred Stock

$0.001 Par Value

Common Stock

Additional

Total

Series B

$0.001 Par Value

Paid-In

Accumulated

Shareholders'

Shares

Amount

Shares

Amount

Capital

Deficit

Balance

December 31, 2018

49,999

533,781,064

534,000

67,289,000

(67,973,000

)

(150,000

)

Net Loss

(436,000

)

(436,000

)

Blance

March 31, 2019

49,999

533,781,064

534,000

67,289,000

(68,409,000

)

(586,000

)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	THREE MONTHS ENDED
	MARCH 31,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(732,000	)	$	(436,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		-			1,000
Loss on fair value adjustment of investments		553,000			215,000
Amortization of debt discount		7,000			-
Changes in:
Prepaid expenses		(5,000	)		(6,000	)
Accounts payable and accrued expenses		77,000			117,000
Deposit for asset sale		-			10,000

Net cash used in operating activities		(100,000	)		(99,000	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets		(4,000	)		(2,000	)
Proceeds from sale of investments		84,000			-

Net cash provided by (used in) investing activities		80,000			(2,000	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable		-			50,000
Net cash provided by financing activities		-			50,000

NET DECREASE IN CASH		(20,000	)		(51,000	)
CASH, BEGINNING OF PERIOD		261,000			87,000

CASH, END OF PERIOD	$	241,000		$	36,000

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid	$	-		$	-
Income taxes paid	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

NOTE 1 – BASIS OF PRESENTATION

The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2019, filed on April 14, 2020. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

As of March 31, 2020, the Company has cumulative losses totaling $69,927,000 and negative working capital of $1,612,000. The Company incurred a net loss of $732,000 for the three months ended March 31, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Because of these conditions, the Company will require additional working capital to develop business operations. Management’s plans are to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

CASH CONCENTRATION:

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2020 and December 31, 2019, we had cash balances of $0 and $0 exceeding the federally insured limits.

PROPERTY AND EQUIPMENT:

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes.

INTANGIBLE ASSETS:

License Agreements

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. At March 31, 2020 and December 31, 2019, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2020, the Company received $300,000 and reduced the due from the sale of assets. As of March 31, 2020, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds.

REVENUE RECOGNITION:

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2019, consisted of the following:

	Total fair value at March 31, 2020		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	408,000	$	408,000	$	-	$	-

	Total fair value at December 31, 2019		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Investment in equity securities	$	1,045,000	$	1,045,000	$	-	$	-

Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2020 and December 31, 2019 because of the relative short term nature of these instruments.

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

As of March 31, 2020, the Company holds approximately 11% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

ACCOUNTING FOR LEASES

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements.

INCOME TAXES

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.

Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

BASIC AND DILUTED LOSS PER SHARE

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2020 and 2019, 31,697,917 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share as the effect of these shares on earnings per share would have been anti-dilutive.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

STOCK BASED COMPENSATION

In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13. The implementation of this standard did not have any material impact on our consolidated financial statements.

The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements except “Fair Value measurements.”

NOTE 3 – INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS)

As of March 31, 2020, the Company owns 56,516,508 shares of Imagion (1,000,000 restricted shares for prepaid notes interests – see Note 4), resulting in a noncontrolling interest of Imagion’s issued and outstanding common stock. Initially, the Company held approximately 31% of Imagion’s total issued and outstanding common stock and was later was decreased to approximately 11%. Based upon Imagion’s trading price on March 31, 2020, approximately $0.007 per share, the fair value of the Imagion shares was approximately $408,000. During the three months ended March 31, 2020, the Company recorded a loss in its investment of $553,000.

On March 25, 2020, Imagion announced that shareholders will be offered two new shares for every five shares held at March 30, 2020. With new share, shareholders will receive a free attaching new option. New option will have an exercise price of 3 cents (Australian currency) and term of three years. The offer will close on April 20, 2020. The Company has the right to buy 22,606,603 new shares of Imagion and the market value at March 31, 2020 is $13,813. The Company elected not to purchase additional shares of Imagion and the option expired in April 2020.

During the three months ended March 31, 2020, the Company sold 4,000,000 shares of Imagion and received cash proceeds of $84,000.

Below is reconciliation for the changes to the investment in Imagion for the three months ended March 31, 2020:

Balance as of December 31, 2019	$	1,045,000
Change due to the sale of securities		(84,000	)
Change in the fair value of securities		(553,000	)
Balance as of March 31, 2020	$	408,000

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

NOTE 4 – NOTES PAYABLE

On October 17, 2019, The Company executed a secured note with a related party, a director of the Company, for $100,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.0257 per share with 2 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2020 was $4,600.

On October 17, 2019, The Company executed a secured note with an individual for $50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.0257 per share with 1 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2020 was $2,400.

	As of March 31, 2020
Notes payable	$	150,000
Less: Discounts on notes payable		(65,000	)
Notes payable, net of discounts	$	85,000

NOTE 5 – OPTIONS AND WARRANTS

A summary of the Company’s stock option activity and related information is as follows:

	Number of Options		Exercise Price Per Share		Weighted Average Exercise Price		Number of Options Exercisable
Outstanding as of December 31, 2019		22,075,000	$	0.07	$	.07		22,075,000
Granted		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		-		-
Outstanding as of March 31, 2020		22,075,000	$	0.07	$	0.07		22,075,000

Exercise prices and weighted-average contractual lives of 22,075,000 stock options outstanding as of March 31, 2020 are as follows:

				Options Outstanding		Options Exercisable
Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Number Exercisable
$	0.05		3,000,000		5.24		3,000,000
$	0.06		6,000,000		4.62		6,000,000
$	0.07		9,000,000		1.13		9,000,000
$	0.08		575,000		0.68		575,000
$	0.14		3,000,000		4.24		3,000,000
$	0.02		500,000		4.25		500,000

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

The fair value for options granted were determined using the Black-Scholes option-pricing model.

Warrants:

The Company issued the following warrants at the corresponding weighted average exercise price as of March 31, 2020.

	Number of Warrants			Exercise Price Per Share		Weighted Average Exercise Price		Number of Warrants Exercisable
Outstanding as of December 31, 2019		9,700,000		$	0.07	$	0.07		9,700,000
Granted		-			-		-		-
Exercised		-			-		-		-
Expired		(2,500,000	)		0.12		0.12		(2,500,000	)
Outstanding as of March 31, 2020		7,200,000							7,200,000

Grant date	Number of Warrants		Exercise Price		Contractual Life Remaining	Number of Shares Exercisable
April 2012		6,000,000	$	0.05	0.6 years		6,000,000
July 2015		300,000	$	0.05	0.2 years		300,000
August 2015		300,000	$	0.05	0.3 years		300,000
September 2015		300,000	$	0.05	0.4 years		300,000
October 2015		300,000	$	0.05	0.5 years		300,000

		7,200,000					7,200,000

The fair value for warrants granted were determined using the Black-Scholes option-pricing model.

NOTE 6 – LICENSE AGREEMENT

On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products.

During the three months ended March 31, 2020, the Company received $0 as a minimum royalty payment.

Table of Contents

MANHATTAN SCIENTIFICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019

(UNAUDITED)

NOTE 7 – COMMITMENTS AND CONTINGENCIES

Legal matter contingencies

The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

Lease

The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. During the year ended December 31, 2019, the lease was assigned to a third party entity. The lease was able to be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary date of the lease. The Company adopted ASC 842 on January 1, 2019 and which had no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore is not required to be capitalized.

NOTE 8 – RELATED PARTY TRANSACTIONS

As of March 31, 2020 and December 31, 2019, the Company had accrued expenses to related parties of approximately $667,000 and $583,750. During the three months ended March 31, 2020, the Company reclassified $1,276,000 from accrued expenses related party to accrued expenses after the Company reevaluated its related party transactions.

As of March 31, 2020, the amounts are due to the Company’s sole officer for compensation $188,000 and the chairman of the board for compensation of $439,000 and the members of the board of directors of $40,000.

As of March 31, 2020 and December 31, 2019, the Company had $100,000 and $100,000, respectively, of principal balance of notes payable due to a director of the Company. (See Note 4)

NOTE 9 – SUBSEQUENT EVENTS

As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted.

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2020 to the date these financial statements were issued, and there were no other material subsequent events to disclose in these financial statements, except as noted.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward Looking Statements

This Form 10-Q contains “forward-looking” statements including statements regarding our expectations of our future operations. For this purpose, any statements contained in this Form 10-Q that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” or “continue” or comparable terminology are intended to identify forward-looking statements. These statements by their nature involve substantial risks and uncertainties, and actual results may differ materially depending on a variety of factors, many of which are not within our control. These factors include, but are not limited to, economic conditions generally and in the industries in which we may participate. In addition, these forward-looking statements are subject, among other things, to our successful completion of the research and development of our technologies; successful commercialization of our technologies; successful protection of our patents; and effective significant industry competition from various entities whose research and development, financial, sales and marketing and other capabilities far exceeds ours. In light of these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, we undertake no obligation to announce publicly revisions we make to these forward-looking statements to reflect the effect of events or circumstances that may arise after the date of this report.

OVERVIEW

Manhattan Scientifics, Inc. (the “Company” or “Manhattan Scientifics”), a Delaware corporation, was established on July 31, 1992 and has one operating wholly-owned subsidiary: Metallicum, Inc., (“Metallicum”). Manhattan Scientifics is focused on technology transfer and commercialization of these transformative technologies.

The Company operates as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in various fields, with emphasis in the areas of nanotechnology. Nanotechnology is the use and manipulation of matter on an atomic and molecular scale. To achieve this goal, the Company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, scientists and leaders in industry and government. The Company and its executives have a long-standing relationship with Los Alamos Laboratories in New Mexico.

In June 2008, we acquired Metallicum and its licensed patented technology. We entered into a stock purchase agreement with Metallicum to acquire all of the outstanding capital in exchange for 15,000,000 restricted shares of our common stock. An additional 15,000,000 shares of our common stock will be payable to Metallicum in the event of meeting certain milestones. At December 31, 2011, one milestone was met. Metallicum was granted an exclusive license by The Los Alamos National Laboratory on patents related to nanostructured metals. In September 2009, we entered into a technology transfer agreement and sale with Carpenter Technology Corporation, (“Carpenter”) wherein Carpenter was to fully develop, manufacture and market a new class of high strength metals. On February 11, 2015, the Company and Carpenter entered into a Settlement Agreement and Mutual Release pursuant to which the parties provided a full release of one another, Carpenter paid the Company $8,000,000, Carpenter transferred to the Company all intellectual and physical property that was part of the original agreement, Carpenter agreed to provide follow-on technical assistance and Carpenter provided a list of all customers and contacts.

On May 31, 2011, we entered into an Agreement and Plan of Reorganization to acquire Senior Scientific. The total purchase price was 21,668,000 restricted shares of our common stock (less 7,667,000 shares previously issued pursuant to an option agreement). As a result of this acquisition, Senior Scientific owned patented technologies that can use biosafe nanoparticles and sensitive magnetic sensors to detect and measure cancer cells in biopsies or in the human body with the potential to transform how cancer is detected and treated. On November 17, 2016, Senior Scientific merged with and into Imagion, a Nevada company. Following the merger, Imagion held all of the liabilities, obligations and assets of Senior Scientific and the Company continued as the sole equity holder of Imagion. On November 29, 2016, the Company announced a plan to have Imagion pursue an IPO and listing on the Australian Stock Exchange (ASX). As of March 31, 2020, Manhattan Scientifics presently owns 55,516,508 shares of Imagion, with a fair market value of approximately $408,000, based upon the closing price per share of Imagion common stock on the Australian Stock Exchange. The Company accounts for its investment in Imagion in accordance with ASC 825-10 and elected fair value option. We initially held 31% of the total issued and outstanding shares of Imagion and had one seat on the Board of Directors of Imagion. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings. As of March 31, 2020, we hold approximately 12% of the total issued and outstanding shares of Imagion and no longer have a seat on the Board of Directors of Imagion.

Table of Contents

On May 1, 2019, Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), and Metallicum, Inc., a wholly-owned subsidiary of the Company, entered into an Overarching Agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. The Company anticipates royalty income as the nanotitanium is commercialized for use in medial prosthetics. Royalties will be 10% on sales of licensed dental products and an average of 5% in all other sales of licensed products.

RESULTS OF OPERATIONS

THREE MONTHS ENDED MARCH 31, 2020 COMPARED TO THREE MONTHS ENDED MARCH 31, 2019

GENERAL AND ADMINISTRATIVE. General and administrative expenses consist of consultants, contractors, accounting, legal, travel, rent, telephone and other day-to-day operating expenses. General and administrative expenses were $169,000 for the three months ended March 31, 2020 compared with $220,000 for the three months ended March 31, 2019. The primary decrease in general and administrative expenses was the result of the decrease in accounting and legal expenses.

RESEARCH AND DEVELOPMENT. Research and development was $3,000 for the three months ended March 31, 2020 compared with $1,000 for the three months ended March 31, 2019. The decrease in research and development was based on the departure of its chief scientist and the Company was in the process of licensing its technology a third party.

OTHER INCOME (EXPENSES). Total other expense for the three months ended March 31, 2020 totaled $560,000 compared to $215,000 for the three months ended March 31, 2019. This is primarily attributable to the loss on fair value adjustments of its investment in Imagion during the period.

NET LOSS. During the three months ended March 31, 2020, the Company incurred a net loss of $732,000, compared to a net loss of $436,000 for the three months ended March 31, 2019. The increase in the net loss is mainly attributable to the increase in the loss on fair value adjustment.

LIQUIDITY AND CAPITAL RESOURCES

Stockholders’ deficit totaled $1,737,000 on March 31, 2020 and the working capital deficit was $1,612,000 on such date. We had a decrease of $20,000 in cash and cash equivalents for the three months ended March 31, 2020.

Based upon current projections, our principal cash requirements for the next 12 months consists of (1) fixed expenses, including payroll, investor relations services, public relations services, bookkeeping services, consultant services, and rent; and (2) variable expenses, including technology research and development, milestone payments and intellectual property protection, and additional scientific consultants. As of March 31, 2020, we had $241,000 in cash. We believe our current cash position is not sufficient to maintain our operations for the next twelve months. Accordingly, we will need to engage in equity or debt financings to secure additional funds. If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

Table of Contents

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of our patents, fair value of our common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

Property and equipment:

Intangible Assets:

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. The value attributable to license agreements is being amortized over the period of its estimated benefit period of 10 years. Under the terms of the agreement the Company is required to pay an annual license fee of $10,000 and, may be required to pay royalties, as defined, to the licensors.

Table of Contents

Due from the Sale of Assets:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on reameasurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

Revenue Recognition:

Accounting for Leases:

Stock Based Compensation:

Table of Contents

Fair Value Measurements:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

Basic and Diluted Loss Per Share:

OFF BALANCE SHEET ARRANGEMENTS

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations liquidity, capital expenditures or capital resources and would be considered material to investors.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to include disclosure under this item.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

We conducted an evaluation under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures also include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive and principal financial officers concluded as of March 31, 2020 that our disclosure controls and procedures were not effective at the reasonable assurance level due to the material weaknesses in our internal controls over financial reporting discussed immediately below.

Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected.

Management identified the following material weakness during its assessment of internal controls over financial reporting:

Resources: We had one full-time employee in general management and no full-time employees with the requisite expertise in the key functional areas of finance and accounting. As a result, there is a lack of proper segregation of duties necessary to insure that all transactions are accounted for accurately and in a timely manner.

Written Policies & Procedures: We need to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions, and prepare, review and submit SEC filings in a timely manner.

Audit Committee: We do not have, and are not required, to have an audit committee. An audit committee would improve oversight in the establishment and monitoring of required internal controls and procedures.

(b) Changes In Internal Control Over Financial Reporting

During the quarter ended March 31, 2020, the Company prepared written policies and procedures for accounting and financial reporting to establish a formal process to close our books monthly on an accrual basis and account for all transactions, including equity transactions. There were no other changes in our internal controls over financial reporting during this fiscal quarter that materially affected, or is reasonably likely to have a materially affect, on our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject from time to time to litigation, claims and suits arising in the ordinary course of business. As of March 31, 2020, we were not a party to any material litigation, claim or suite whose outcome could have a material effect on our financial statements.

ITEM 1A. RISK FACTORS

An investment in the Common Stock involves a high degree of risk. In addition to the other information in this report, the following risk factors should be considered carefully in evaluating the Company and our business. If you decide to buy our securities, you should be able to afford a complete loss of your investment.

WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND COMMERCIALIZE OUR NEW TECHNOLOGIES WHICH WOULD RESULT IN CONTINUED LOSSES.

We are currently developing new technologies and a commercial product. We have generated our first revenues but we are unable to project when we will again generate significant revenue or achieve regular profitability, if at all. As is the case with any new technology, we expect the development process to continue. We cannot assure that our resources will be able to develop and commercialize our technology fast enough to meet market requirements. We can also not assure that our technology will gain market acceptance and that we will be able to overcome obstacles, such as potential FDA approvals. The failure to successfully develop and commercialize the technologies would result in continued losses and may require us to curtail operations.

THE SUCCESS OF OUR BUSINESS MAY REQUIRE CONTINUED FUNDING. IF WE CANNOT RAISE THE MONEY WE NEED TO SUPPORT OUR OPERATIONS UNTIL WE EARN SIGNIFICANT REVENUES, WE MAY BE REQUIRED TO CURTAIL OR TO CEASE OUR OPERATIONS AND YOU COULD LOSE YOUR ENTIRE INVESTMENT.

Our ability to develop our business depends upon our receipt of money to continue our operations while we introduce our products and a market for them develops. If this funding is not received as needed, it is unlikely that we could continue our business, in which case you would lose your entire investment. Our ability to access the capital markets has been hindered generally by the general difficult economic climate, beginning in 2008, for small technology concept companies, without significant revenues or earnings.

To the extent that we need additional funding, we cannot assure you that such financing will be available to us when needed, on commercially reasonable terms, or at all. If we are unable to obtain additional financing, we may be required to curtail the commercialization of our products and possibly cease our operations.

OUR ABILITY TO EFFECTUATE OUR BUSINESS MODEL MAY BE LIMITED, WHICH WOULD ADVERSELY EFFECT OUR BUSINESS AND FINANCIAL CONDITIONS.

Our future performance will depend to a substantial degree upon our ability to effectuate and generate revenues from our licensing and royalty business model. As a result, we may continue to incur substantial operating losses until such time as we are able to generate revenues from the sale or license of our products. There can be no assurance that businesses and customers will adopt our technology and products, or that businesses and prospective customers will agree to pay for or license our products. In the event that we are not able to significantly increase the number of customers that purchase or license our products, or if we are unable to charge the necessary prices or license fees, our financial condition and results of operations will be materially and adversely affected.

Table of Contents

WE MAY FACE STRONG COMPETITION FROM LARGER, ESTABLISHED COMPANIES.

We likely will face intense competition from other companies, both globally and within the United States, in the development of our cancer detection technology and nano-metal technologies, virtually all of which can be expected to have longer operating histories, greater name recognition, larger installed customer bases and significantly more financial resources and research and development facilities than Manhattan Scientifics. There can be no assurance that developments by our current or potential competitors will not render our proposed products obsolete.

WE MAY NOT BE ABLE TO ADEQUATELY PROTECT OUR INTELLECTUAL PROPERTY OR WE COULD BECOME INVOLVED IN LITIGATION WITH OTHERS REGARDING OUR INTELLECTUAL PROPERTY. EITHER OF THESE EVENTS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS.

We rely on a combination of intellectual property law, nondisclosure, trade secret and other contractual and technical measures to protect our proprietary right. Our success will depend, in part, on our technology’s commercial viability and on the strength of our intellectual property rights. However, we cannot assure you that these provisions will be adequate to protect our intellectual property. In addition, the laws of certain foreign countries do not protect intellectual property rights to the same extent as the laws of the United States.

Although we believe that our intellectual property does not infringe upon the proprietary rights of third parties, competitors may claim that we have infringed on their products.

We could incur substantial costs in defending ourselves in suits brought against us for alleged infringement of another party’s intellectual property rights as well as in enforcing our rights against others, and if we are found to infringe, the manufacture, sale and use of our or our customers’ or partners’ products could be enjoined. Any claims against us, with or without merit, would likely be time-consuming, requiring our management team to dedicate substantial time to addressing the issues presented. Furthermore, the parties bringing claims may have greater resources than we do.

OUR MANAGEMENT IS ABLE TO EXERCISE SIGNIFICANT INFLUENCE OVER ALL MATTERS REQUIRING SHAREHOLDER APPROVAL.

Our existing directors and executive officers are the beneficial owners of approximately 25% of the outstanding shares of common stock, excluding stock options and warrants. As a result, our existing directors, executive officers, principal shareholders and their respective affiliates, if acting together, would be able to exercise significant influence over all matters requiring shareholder approval, including the election of directors and the approval of significant corporate transactions. Such concentration of ownership may also have the effect of delaying or preventing a change in control of our company.

THE TRADING PRICE OF OUR COMMON STOCK MAY DECREASE DUE TO FACTORS BEYOND OUR CONTROL.

The trading price of our common stock is subject to significant fluctuations in response to numerous factors, including without limitation:

	·	variations in anticipated or actual results of operations;

	·	announcements of new products or technological innovations by us or our competitors;

	·	changes in earnings estimates of operational results by analysts;

	·	inability of market makers to combat short positions on the stock;

	·	an overall downturn in the financial markets and stock markets;

	·	the use of stock to pay employees and consultants if sufficient working capital is not available;

	·	inability of the market to absorb large blocks of stock sold into the market; and

	·	developments or disputes concerning our intellectual property.

Table of Contents

Moreover, the stock market from time-to-time has experienced extreme price and volume fluctuations, which have particularly affected the market prices for small technology companies without significant revenues. These broad market fluctuations may adversely affect the market price of our Common Stock. If our shareholders sell substantial amounts of their common stock in the public market, the price of our common stock could fall. These sales also might make it more difficult for us to sell equity or equity-related securities in the future at a price we deem appropriate.

WE HAVE NOT PAID CASH DIVIDENDS AND IT IS UNLIKELY THAT WE WILL PAY CASH DIVIDENDS IN THE FORESEEABLE FUTURE.

We plan to use all of our earnings, to the extent we have significant earnings, to fund our operations. We do not plan to pay any cash dividends in the foreseeable future. We cannot guarantee that we will, at any time, generate sufficient surplus cash that would be available for distribution as a dividend to the holders of our Common Stock. You should not expect to receive cash dividends on our Common Stock.

WE MAY NOT HAVE SUFFICIENT CAPITAL TO RUN OUR OPERATIONS.

If we are unable to obtain further financing, it may jeopardize our ability to continue our operations. To the extent that additional capital is raised through the sale of equity and/or convertible debt securities, the issuance of such securities could result in dilution to our shareholders and/or increased debt service commitments. If adequate funds are not available, we may be unable to sufficiently develop or maintain our existing operations.

WE HAVE THE ABILITY TO ISSUE ADDITIONAL SHARES OF OUR COMMON STOCK WITHOUT ASKING FOR SHAREHOLDER APPROVAL, WHICH COULD CAUSE YOUR INVESTMENT TO BE DILUTED.

Our Certificate of Incorporation currently authorizes the Board of Directors to issue up to 950,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. The power of the Board of Directors to issue shares of Common Stock or warrants or options to purchase shares of Common Stock is generally not subject to shareholder approval. Accordingly, any additional issuance of our Common Stock may have the effect of further diluting your investment.

We require substantial working capital to fund our business. If we raise additional funds through the issuance of equity, equity-related or convertible debt securities, those securities may have rights, preferences or privileges senior to those of the holders of our Common Stock. The issuance of additional Common Stock or securities convertible into Common Stock by our management will also have the effect of further diluting the proportionate equity interest and voting power of holders of our Common Stock.

LIMITED PUBLIC MARKET FOR OUR COMMON STOCK MAY AFFECT OUR SHAREHOLDERS' ABILITY TO SELL OUR COMMON STOCK.

Our Common Stock currently is quoted on the OTCQB operated by OTC Markets, which is generally considered to be a less efficient market than national exchanges. Consequently, the liquidity of our securities could be impaired, not only in the number of securities which could be bought and sold, but also through SEC regulations, delays in the timing of transactions, difficulties in obtaining price quotations, reduction in security analysts' and the new media's coverage of us, if any, and lower prices for our securities than might otherwise be attained. This circumstance could have an adverse effect on the ability of an investor to sell any shares of our common stock as well as on the selling price for such shares. In addition, the market price of our common stock may be significantly affected by various additional factors, including, but not limited to, our business performance, industry dynamics or changes in general economic conditions.

Table of Contents

APPLICABILITY OF "PENNY STOCK RULES" TO BROKER-DEALER SALES OF OUR COMMON STOCK COULD HAVE A NEGATIVE EFFECT ON THE LIQUIDITY AND MARKET PRICE OF OUR COMMON STOCK.

A penny stock is generally a stock that is not listed on national securities exchange and is quoted on the "pink sheets" or on the OTC Bulletin Board, has a price per share of less than $5.00 and is issued by a company with net tangible assets less than $5 million.

The penny stock trading rules impose additional duties and responsibilities upon broker-dealers and salespersons effecting purchase and sale transactions in Common Stock and other equity securities, including determination of the purchaser's investment suitability, delivery of certain information and disclosures to the purchaser, and receipt of a specific purchase agreement before effecting the purchase transaction.

Many broker-dealers will not affect transactions in penny stocks, except on an unsolicited basis, in order to avoid compliance with the penny stock trading rules. When our Common Stock is subject to the penny stock trading rules, such rules may materially limit or restrict the ability to resell our Common Stock, and the liquidity typically associated with other publicly traded equity securities may not exist.

WE ARE EVALUATING THE EFFECTS OF COVID-19 ON OUR BUSINESS OPERATIONS.

While the complete impact on our business from the recent outbreak of the COVID-19 coronavirus is unknown at this time and difficult to predict, various aspects of our business are being adversely affected by it and may continue to be adversely affected.

As of the date hereof, COVID-19 has been declared a pandemic by the World Health Organization, has been declared a National Emergency by the United States Government and has resulted in several states being designated disaster zones. COVID-19 coronavirus caused significant volatility in global markets, including the market price of our securities. The spread of COVID-19 coronavirus has caused public health officials to recommend precautions to mitigate the spread of the virus, especially as to travel and congregating in large numbers. In addition, certain states and municipalities have enacted, and additional cities are considering, quarantining and “shelter-in-place” regulations which severely limit the ability of people to move and travel, and require non-essential businesses and organizations to close.

Thus far, these restrictions have adversely affected our business, results of operations and financial condition. It is unclear how such restrictions, should they continue for an extended period, which will contribute to a general slowdown in the global economy, will affect our business, results of operations, financial condition, and our future strategic plans.

To date, the demand for our products and services has decreased and the ability of our customers to make payment for the products and services they purchased has been negatively impacted. It is unclear how a prolonged outbreak with travel, commercial and other similar restrictions, may adversely affect our business operations and the business operations of our customers and suppliers. However, we anticipate a prolonged period will have a negative effect on our business operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

Table of Contents

ITEM 6. EXHIBITS

Index to Exhibits

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

EX-101.INS**		XBRL Instance Document

EX-101.SCH**		XBRL Taxonomy Extension Schema Document

EX-101.CAL**		XBRL Taxonomy Extension Calculation Linkbase

EX-101.DEF**		XBRL Taxonomy Extension Definition Linkbase

EX-101.LAB**		XBRL Taxonomy Extension Labels Linkbase

EX-101.PRE**		XBRL Taxonomy Extension Presentation Linkbase

_________________

** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 20th day of May, 2020.

	MANHATTAN SCIENTIFICS, INC.

	By:	/s/ Emmanuel Tsoupanarias
	Name:	Emmanuel Tsoupanarias
	Title:	Chief Executive Officer (Principal Executive, Financial and Accounting Officer)

EX-31.1 2 mhtx_ex311.htm CERTIFICATION mhtx_ex311.htm

EXHIBIT 31.1

CERTIFICATIONS

I, Emmanuel Tsoupanarias, certify that:

1.	I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2020 (the “report”) of Manhattan Scientifics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: May 20, 2020	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(principal executive, financial and accounting officer)

EX-32.1 3 mhtx_ex321.htm CERTIFICATION mhtx_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Manhattan Scientifics, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of his knowledge, that:

	(1)	The Quarterly Report of Form 10-Q for the period ending March 31, 2020 (the “Report”) of the Company complies in all material respects with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 20, 2020	By:	/s/ Emmanuel Tsoupanarias
		Emmanuel Tsoupanarias
		Chief Executive Officer
		(principal executive, financial and accounting officer)

EX-101.INS 4 mhtx-20200331.xml XBRL INSTANCE DOCUMENT 0001099132 2020-01-01 2020-03-31 0001099132 2020-05-20 0001099132 2020-03-31 0001099132 2019-12-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2020-03-31 0001099132 mhtx:ClassAConvertiblePreferredStockMember 2019-12-31 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2020-03-31 0001099132 mhtx:ClassBConvertiblePreferredStockMember 2019-12-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2020-03-31 0001099132 mhtx:ClassCRedeemableConvertiblePreferredStockMember 2019-12-31 0001099132 mhtx:SeriesDconvertiblepreferredStockMember 2020-03-31 0001099132 mhtx:SeriesDconvertiblepreferredStockMember 2019-12-31 0001099132 2019-01-01 2019-03-31 0001099132 2018-12-31 0001099132 us-gaap:CommonStockMember 2018-12-31 0001099132 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001099132 us-gaap:RetainedEarningsMember 2018-12-31 0001099132 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001099132 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001099132 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001099132 2019-03-31 0001099132 us-gaap:CommonStockMember 2019-03-31 0001099132 us-gaap:SeriesAPreferredStockMember 2019-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001099132 us-gaap:RetainedEarningsMember 2019-03-31 0001099132 us-gaap:CommonStockMember 2019-12-31 0001099132 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001099132 us-gaap:RetainedEarningsMember 2019-12-31 0001099132 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001099132 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001099132 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001099132 us-gaap:CommonStockMember 2020-03-31 0001099132 us-gaap:SeriesAPreferredStockMember 2020-03-31 0001099132 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001099132 us-gaap:RetainedEarningsMember 2020-03-31 0001099132 mhtx:TotalFairValueMember 2020-03-31 0001099132 mhtx:TotalFairValueMember 2019-12-31 0001099132 mhtx:QuotedPricesInActiveMarketsForIdenticalAssetsMember mhtx:LevelOneMember 2020-03-31 0001099132 mhtx:QuotedPricesInActiveMarketsForIdenticalAssetsMember mhtx:LevelOneMember 2019-12-31 0001099132 mhtx:SignificantOtherObservableInputsMember mhtx:LevelTwoMember 2020-03-31 0001099132 mhtx:SignificantOtherObservableInputsMember mhtx:LevelTwoMember 2019-12-31 0001099132 mhtx:SignificantUnobservableInputsMember mhtx:LevelThreeMember 2020-03-31 0001099132 mhtx:SignificantUnobservableInputsMember mhtx:LevelThreeMember 2019-12-31 0001099132 2019-05-01 2019-05-31 0001099132 2019-01-01 2019-12-31 0001099132 2018-01-01 2018-12-31 0001099132 mhtx:ImagionBiosystemsIncMember 2020-03-31 0001099132 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001099132 mhtx:LosAlamosNationalSecurityLLCMember mhtx:PatentLicenseAgreementMember 2009-01-01 2009-12-31 0001099132 mhtx:ImagionBiosystemsIncMember 2019-12-31 0001099132 mhtx:ImagionBiosystemsIncMember 2020-01-01 2020-03-31 0001099132 mhtx:ImagionBiosystemsIncMember 2020-03-01 2020-03-25 0001099132 mhtx:RelatedPartyMember 2019-10-01 2019-10-17 0001099132 mhtx:RelatedPartyMember 2020-01-01 2020-03-31 0001099132 us-gaap:IndividualMember 2019-10-01 2019-10-17 0001099132 us-gaap:IndividualMember 2020-01-01 2020-03-31 0001099132 mhtx:ExercisePriceRangeTwoMember 2020-03-31 0001099132 mhtx:ExercisePriceRangeTwoMember 2020-01-01 2020-03-31 0001099132 mhtx:ExercisePriceRangeThreeMember 2020-03-31 0001099132 mhtx:ExercisePriceRangeThreeMember 2020-01-01 2020-03-31 0001099132 mhtx:ExercisePriceRangeFourMember 2020-03-31 0001099132 mhtx:ExercisePriceRangeFourMember 2020-01-01 2020-03-31 0001099132 mhtx:ExercisePriceRangeFiveMember 2020-03-31 0001099132 mhtx:ExercisePriceRangeFiveMember 2020-01-01 2020-03-31 0001099132 mhtx:ExercisePriceRangeSixMember 2020-03-31 0001099132 mhtx:ExercisePriceRangeSixMember 2020-01-01 2020-03-31 0001099132 mhtx:ExercisePriceRangeSevenMember 2020-03-31 0001099132 mhtx:ExercisePriceRangeSevenMember 2020-01-01 2020-03-31 0001099132 mhtx:WarrantsMember 2020-01-01 2020-03-31 0001099132 mhtx:April2012Member 2020-03-31 0001099132 mhtx:April2012Member 2020-01-01 2020-03-31 0001099132 mhtx:July2015Member 2020-03-31 0001099132 mhtx:July2015Member 2020-01-01 2020-03-31 0001099132 mhtx:August2015Member 2020-03-31 0001099132 mhtx:August2015Member 2020-01-01 2020-03-31 0001099132 mhtx:September2015Member 2020-03-31 0001099132 mhtx:September2015Member 2020-01-01 2020-03-31 0001099132 mhtx:October2015Member 2020-03-31 0001099132 mhtx:October2015Member 2020-01-01 2020-03-31 0001099132 mhtx:SoleOfficerMember 2020-03-31 0001099132 mhtx:ChairmanMember 2020-03-31 0001099132 mhtx:BoardOfDirectorMember 2020-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure MANHATTAN SCIENTIFICS INC 0001099132 10-Q false --12-31 true false false Yes 2020-03-31 Non-accelerated Filer Q1 2020 557781064 Yes

241000

261000

18000

13000

300000

559000

574000

408000

1045000

8000

4000

600000 600000

2000

1577000

2225000

1504000

1510250

667000

583750

2171000

2094000

85000

78000

85000

78000

2256000

2172000

558000

67632000

-69927000

-69195000

-1737000

-1005000

1577000

2225000

1058000

.001

447804

950000000

557781064

182525

250000

49999

14000

105761

169000

220000

3000

1000

172000

221000

-172000

-221000

-553000

-215000

-7000

-560000

-215000

-732000

-436000

557781064

533781064

-0.00

557781064

533781064

-0.00

533781064

49999

-150000

534000

67289000

-67973000

-436000

533781064

49999

-586000

534000

67289000

-68409000

557781064

49999

-1005000

558000

67632000

-69195000

-732000

557781064

49999

-1737000

558000

67632000

-69927000

1000

553000

215000

7000

-5000

-6000

77000

117000

10000

-100000

-99000

-4000

-2000

84000

80000

-2000

50000

-20000

-51000

87000

36000

<div style="TEXT-ALIGN:justify; FONT: 10pt TIMES NEW ROMAN">The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2019, filed on April 14, 2020. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented. Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.  The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements. As of March 31, 2020, the Company has cumulative losses totaling $69,927,000 and negative working capital of $1,612,000. The Company incurred a net loss of $732,000 for the three months ended March 31, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  Because of these conditions, the Company will require additional working capital to develop business operations. Management’s plans are to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> BASIS OF CONSOLIDATION:   The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.   USE OF ESTIMATES:   The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.   CASH CONCENTRATION:   The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2020 and December 31, 2019, we had cash balances of $0 and $0 exceeding the federally insured limits.   PROPERTY AND EQUIPMENT:   Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes.   INTANGIBLE ASSETS:   License Agreements   In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. At March 31, 2020 and December 31, 2019, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.   DUE FROM THE SALE OF ASSETS:   Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.   Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell.  Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss.  Gains are not recognized in excess of any cumulative impairment loss.   During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018.  During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million.  The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019.  The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1.  During May 2020, the Company received $300,000 and reduced the due from the sale of assets.   As of March 31, 2020, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds.    REVENUE RECOGNITION:   The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.    FAIR VALUE OF FINANCIAL INSTRUMENTS   The Company recognized the fair value of financial instruments in accordance with  FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:   Level 1 — Quoted prices for identical assets and liabilities in active markets;   Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and   Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.   The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.   Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2019, consisted of the following:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Total fair value at March 31, 2020</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Quoted prices in active markets for identical assets (Level 1)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant other observable inputs (Level 2)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Total fair value at December 31, 2019</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Quoted prices in active markets for identical assets (Level 1)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Significant other observable inputs (Level 2)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,045,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,045,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table>   Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2020 and December 31, 2019 because of the relative short term nature of these instruments.   During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.    As of March 31, 2020, the Company holds approximately 11% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320.  Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value.  The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD.  Any change in the value is reported on the income statement as an unrealized gain or loss.    ACCOUNTING FOR LEASES   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs.  Consequently, financial information for the comparative periods will not be updated.  Upon adoption, there was no material impact to the financial statements.   INCOME TAXES   The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.   ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.   Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.   BASIC AND DILUTED LOSS PER SHARE   In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.  As of March 31, 2020 and 2019, 31,697,917 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share as the effect of these shares on earnings per share would have been anti-dilutive.   STOCK BASED COMPENSATION   In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting.  The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019.  Upon adoption, there was no material impact to the financial statements.    RECENT ACCOUNTING PRONOUNCEMENTS   In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13.  The implementation of this standard did not have any material impact on our consolidated financial statements.   The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.   The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements except “Fair Value measurements.”</div>

<div style="TEXT-ALIGN:justify; FONT: 10pt TIMES NEW ROMAN">As of March 31, 2020, the Company owns 56,516,508 shares of Imagion (1,000,000 restricted shares for prepaid notes interests – see Note 4), resulting in a noncontrolling interest of Imagion’s issued and outstanding common stock. Initially, the Company held approximately 31% of Imagion’s total issued and outstanding common stock and was later was decreased to approximately 11%. Based upon Imagion’s trading price on March 31, 2020, approximately $0.007 per share, the fair value of the Imagion shares was approximately $408,000.  During the three months ended March 31, 2020, the Company recorded a loss in its investment of $553,000. On March 25, 2020, Imagion announced that shareholders will be offered two new shares for every five shares held at March 30, 2020. With new share, shareholders will receive a free attaching new option. New option will have an exercise price of 3 cents (Australian currency) and term of three years. The offer will close on April 20, 2020. The Company has the right to buy 22,606,603 new shares of Imagion and the market value at March 31, 2020 is $13,813.  The Company elected not to purchase additional shares of Imagion and the option expired in April 2020. During the three months ended March 31, 2020, the Company sold 4,000,000 shares of Imagion and received cash proceeds of $84,000. Below is reconciliation for the changes to the investment in Imagion for the three months ended March 31, 2020: <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance as of December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,045,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change due to the sale of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(84,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Change in the fair value of securities</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(553,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance as of March 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">408,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">On October 17, 2019, The Company executed a secured note with a related party, a director of the Company, for $100,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.0257 per share with 2 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2020 was $4,600.   On October 17, 2019, The Company executed a secured note with an individual for $50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.0257 per share with 1 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2020 was $2,400.   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> As of March 31, 2020</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:10%;vertical-align:bottom;"> 150,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Less: Discounts on notes payable</td> <td></td> <td style="BORDER-BOTTOM: 1px solid;">  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> (65,000</td> <td style="vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable, net of discounts</td> <td>  </td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;"> 85,000</td> <td></td></tr></table></div>

<div style="TEXT-ALIGN:justify; FONT: 10pt TIMES NEW ROMAN">A summary of the Company’s stock option activity and related information is as follows: <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Number of Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Exercise Price Per Share</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Number of Options Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,075,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,075,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of March 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">22,075,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">22,075,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> Exercise prices and weighted-average contractual lives of 22,075,000 stock options outstanding as of March 31, 2020 are as follows: <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2">Options Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2">Options Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2">Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2">Number Outstanding</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2">Weighted Average Remaining Contractual Life</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;" colspan="2">Number Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td style="width:20%;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">3,000,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">5.24</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">3,000,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.06</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.62</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">6,000,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.07</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">1.13</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">9,000,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.08</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">575,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.68</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">575,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.14</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.24</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">3,000,000</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;white-space: nowrap;">$</td><td>0.02</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">500,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">4.25</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">500,000</td><td style="white-space: nowrap;"> </td></tr></tbody></table> The fair value for options granted were determined using the Black-Scholes option-pricing model. Warrants: The Company issued the following warrants at the corresponding weighted average exercise price as of March 31, 2020. <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Number of Warrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Exercise Price Per Share</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Number of Warrants Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,700,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.07</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9,700,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,500,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,500,000</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding as of March 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">7,200,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">7,200,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Grant date</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Number of Warrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Contractual Life Remaining</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2">Number of Shares Exercisable</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">April 2012</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>0.6 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,000,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">July 2015</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>0.2 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">August 2015</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>0.3 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">September 2015</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>0.4 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">October 2015</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>0.5 years</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">300,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,200,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,200,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The fair value for warrants granted were determined using the Black-Scholes option-pricing model.</div>

<div style="TEXT-ALIGN:justify; FONT: 10pt TIMES NEW ROMAN">On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party.  As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales.  Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products. During the three months ended March 31, 2020, the Company received $0 as a minimum royalty payment.</div>

<div style="TEXT-ALIGN:justify; FONT: 10pt TIMES NEW ROMAN">Legal matter contingencies The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company.  Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted.  Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change. Lease The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. During the year ended December 31, 2019, the lease was assigned to a third party entity. The lease was able to be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary date of the lease. The Company adopted ASC 842 on January 1, 2019 and which had no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore is not required to be capitalized.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">As of March 31, 2020 and December 31, 2019, the Company had accrued expenses to related parties of approximately $667,000 and $583,750.  During the three months ended March 31, 2020, the Company reclassified $1,276,000 from accrued expenses related party to accrued expenses after the Company reevaluated its related party transactions.   As of March 31, 2020, the amounts are due to the Company’s sole officer for compensation $188,000 and the chairman of the board for compensation of $439,000 and the members of the board of directors of $40,000.    As of March 31, 2020 and December 31, 2019, the Company had $100,000 and $100,000, respectively, of principal balance of notes payable due to a director of the Company. (See Note 4)</div>

<div style="TEXT-ALIGN:justify; FONT: 10pt TIMES NEW ROMAN">As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2020 to the date these financial statements were issued, and there were no other material subsequent events to disclose in these financial statements, except as noted.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2020 and December 31, 2019, we had cash balances of $0 and $0 exceeding the federally insured limits.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. At March 31, 2020 and December 31, 2019, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.   Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell.  Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss.  Gains are not recognized in excess of any cumulative impairment loss.   During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018.  During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million.  The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019.  The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1.  During May 2020, the Company received $300,000 and reduced the due from the sale of assets.   As of March 31, 2020, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds. </div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.   Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> The Company recognized the fair value of financial instruments in accordance with  FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:   Level 1 — Quoted prices for identical assets and liabilities in active markets;   Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and   Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.   The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.   Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2019, consisted of the following:   <table style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td>  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Total fair value at March 31, 2020</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Quoted prices in active markets for identical assets (Level 1)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant other observable inputs (Level 2)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td> <td style="white-space: nowrap;">  </td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td class="ffcell" style="width:9%;">  </td> <td style="width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px"> <td>  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Total fair value at December 31, 2019</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Quoted prices in active markets for identical assets (Level 1)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Significant other observable inputs (Level 2)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,045,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,045,000</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;white-space: nowrap;">  </td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;">  </td></tr></table>  Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2020 and December 31, 2019 because of the relative short term nature of these instruments.   During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.    As of March 31, 2020, the Company holds approximately 11% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320.  Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value.  The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD.  Any change in the value is reported on the income statement as an unrealized gain or loss.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs.  Consequently, financial information for the comparative periods will not be updated.  Upon adoption, there was no material impact to the financial statements.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.   ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.   Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.  As of March 31, 2020 and 2019, 31,697,917 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share as the effect of these shares on earnings per share would have been anti-dilutive.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting.  The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019.  Upon adoption, there was no material impact to the financial statements.</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;">In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13.  The implementation of this standard did not have any material impact on our consolidated financial statements.   The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.   The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements except “Fair Value measurements.”</div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Total fair value at March 31, 2020</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Quoted prices in active markets for identical assets (Level 1)</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Significant other observable inputs (Level 2)</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 408,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 408,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Total fair value at December 31, 2019</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Quoted prices in active markets for identical assets (Level 1)</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Significant other observable inputs (Level 2)</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> Significant unobservable inputs (Level 3)</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Investment in equity securities</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 1,045,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 1,045,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td></tr></table></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Balance as of December 31, 2019</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 1,045,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Change due to the sale of securities</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> (84,000</td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Change in the fair value of securities</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (553,000</td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Balance as of March 31, 2020</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 408,000</td> <td style="width:1%;"></td></tr></table></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable</td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 150,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Less: Discounts on notes payable</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (65,000</td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Notes payable, net of discounts</td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 85,000</td> <td style="width:1%;"></td></tr></table></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Options</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Exercise Price Per Share</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Weighted Average Exercise Price</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Options Exercisable</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of December 31, 2019</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 22,075,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.07</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> .07</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 22,075,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Granted</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Exercised</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expired</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of March 31, 2020</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 22,075,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 0.07</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;"> $</td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 0.07</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 22,075,000</td> <td style="width:1%;"></td></tr></table></div>

<div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="2"></td> <td></td> <td></td> <td colspan="2"></td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Options Outstanding</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Options Exercisable</td> <td>  </td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Exercise Price</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Number Outstanding</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Weighted Average Remaining Contractual Life</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;" colspan="2"> Number Exercisable</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:20%;"> 0.05</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:15%;vertical-align:bottom;"> 3,000,000</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:15%;vertical-align:bottom;"> 5.24</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:15%;vertical-align:bottom;"> 3,000,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> $</td> <td> 0.06</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 6,000,000</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 4.62</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 6,000,000</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> $</td> <td> 0.07</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 9,000,000</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 1.13</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 9,000,000</td> <td>  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> $</td> <td> 0.08</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 575,000</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 0.68</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 575,000</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:bottom;"> $</td> <td> 0.14</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 3,000,000</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 4.24</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 3,000,000</td> <td>  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:bottom;"> $</td> <td> 0.02</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 500,000</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 4.25</td> <td></td> <td></td> <td>  </td> <td style="vertical-align:bottom;"> 500,000</td> <td></td></tr></table></div> <div style="font: 10pt TIMES NEW ROMAN; text-align: left;"> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Warrants</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Exercise Price Per Share</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Weighted Average Exercise Price</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Warrants Exercisable</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of December 31, 2019</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 9,700,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.07</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.07</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 9,700,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Granted</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Exercised</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> -</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> Expired</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (2,500,000</td> <td style="width:1%;vertical-align:bottom;"> )</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 0.12</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 0.12</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> (2,500,000</td> <td style="width:1%;vertical-align:bottom;"> )</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> Outstanding as of March 31, 2020</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 7,200,000</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 7,200,000</td> <td style="width:1%;"></td></tr></table>   <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> Grant date</td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Warrants</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Exercise Price</td> <td></td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> Contractual Life Remaining</td> <td>  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;" colspan="2"> Number of Shares Exercisable</td> <td>  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> April 2012</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 6,000,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.05</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td> 0.6 years</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 6,000,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> July 2015</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.05</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td> 0.2 years</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> August 2015</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.05</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td> 0.3 years</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> September 2015</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.05</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td> 0.4 years</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;">  </td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> October 2015</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td style="width:1%;vertical-align:bottom;"> $</td> <td style="width:9%;vertical-align:bottom;"> 0.05</td> <td style="width:1%;"></td> <td style="width:1%;">  </td> <td> 0.5 years</td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;">  </td> <td style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;"> 300,000</td> <td style="width:1%;"></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td></tr> <tr style="height:15px;background-color:#cceeff"> <td></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 7,200,000</td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td> <td style="BORDER-BOTTOM: 3px double;width:1%;">  </td> <td style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;"> 7,200,000</td> <td style="width:1%;"></td></tr></table></div> -1612000

408000

1045000

408000

1045000

300000

250000

1200000

The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1.

1200000

An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained

0.11

31697917

50798182

10000 1045000

-84000

-553000 408000 0.007

56516508

0.31

408000

1000000

553000

Shareholders will be offered two new shares for every five shares held at March 30, 2020. With new share, shareholders will receive a free attaching new option. New option will have an exercise price of 3 cents (Australian currency) and term of three years

22606603

13813

84000

4000000

150000

-65000

100000

0.1

2022-10-17

2000000 0.0257

4600

50000

0.1

2022-10-17

1000000 0.0257

2400

22075000

22075000 0.07

0.07 0.07

0.07 22075000 22075000

3000000

P5Y2M27D

0.05

3000000

6000000

P4Y7M13D

0.06

6000000

9000000

P1Y1M17D

0.07

9000000

575000

P8M5D

0.08

575000

3000000

P4Y2M27D

3000000

0.14

500000

P4Y2M30D

500000

0.02

9700000 -2500000 7200000 0.07 0.12 0.07 0.12 9700000 -2500000 7200000 7200000

7200000

6000000

0.05

P7M6D

6000000

300000

0.05

P2M12D

300000

0.05

P3M18D

300000

0.05

P4M24D

300000

0.05

P5M30D

300000

0.1 For a term of 17 years unless terminated sooner 0.05

The lease was able to be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary date of the lease

667000

583750

1276000

100000

188000

439000

40000

EX-101.SCH 5 mhtx-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - OPTIONS AND WARRANTS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - COMMITMENTS AND CONTIGENCIES link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - OPTIONS AND WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - OPTIONS AND WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - OPTIONS AND WARRANTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - OPTIONS AND WARRANTS (Details 2) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - OPTIONS AND WARRANTS (Details 3) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - LICENSE AGREEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 mhtx-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Class of Stock [Axis] Class A Convertible Preferred Stock [Member] Class B Convertible Preferred Stock [Member] Class C Redeemable Convertible Preferred Stock [Member] Series D convertible preferred Stock [Member] Current assets: Cash Prepaid expenses Due from the sale of assets - current portion Total current assets Investment in equity securities Property and equipment, net Due from the sale of assets Other assets Total assets Current liabilities: Accounts payable and accrued expenses Accrued expenses - related parties Total current liabilities Long-term liabilities: Notes payable, net of discounts Total long-term liabilities Total liabilities Commitments and Contingencies - Note 7 STOCKHOLDERS' EQUITY DEFICIT Preferred Stock Value Common, authorized 950,000,000 shares, 557,781,064 and 557,781,064 shares issued, and outstanding, respectively Additional paid-in-capital Accumulated deficit Total stockholders' deficit TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT Class A Convertible Preferred Stock [Member] Class B Convertible Preferred Stock [Member] Class C Redeemable Convertible Preferred Stock [Member] Capital stock, shares par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Revenue Operating costs: General and administrative expenses Research and development Total operating costs and expenses Loss from operations before other income and expenses Other income and (expenses): Loss on fair value adjustment of investments Interest expense Total other income (expense) NET LOSS LOSS PER COMMON SHARE: Weighted average number of common shares outstanding (Basic) Basic loss per common share Weighted average number of common shares outstanding (Diluted) Diluted loss per common share CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Equity Components [Axis] Common Stock [Member] Preferred Stock Series A [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Balance, shares [Shares, Issued] Balance, shares [Stockholders' Equity Attributable to Parent] Net Loss Balance, shares Balance, shares CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss on fair value adjustment of investments [Assets, Fair Value Adjustment] Amortization of debt discount Changes in: Prepaid expenses [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued expenses [Increase (Decrease) in Accounts Payable and Accrued Liabilities] Deposit for asset sale Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of fixed assets Proceeds from sale of investments Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from notes payable Net cash provided by financing activities NET DECREASE IN CASH CASH, BEGINNING OF PERIOD CASH, END OF PERIOD SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Interest paid Income taxes paid BASIS OF PRESENTATION NOTE 1 - BASIS OF PRESENTATION SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) NOTE 3 - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) NOTES PAYABLE NOTE 4 - NOTES PAYABLE OPTIONS AND WARRANTS NOTE 5 - OPTIONS AND WARRANTS LICENSE AGREEMENT NOTE 6 - LICENSE AGREEMENT COMMITMENTS AND CONTIGENCIES NOTE 7 - COMMITMENTS AND CONTIGENCIES RELATED PARTY TRANSACTIONS NOTE 8 - RELATED PARTY TRANSACTIONS SUBSEQUENT EVENTS NOTE 9 - SUBSEQUENT EVENTS BASIS OF CONSOLIDATION USE OF ESTIMATES CASH CONCENTRATION PROPERTY AND EQUIPMENT INTANGIBLE ASSETS DUE FROM THE SALE OF ASSETS REVENUE RECOGNITION FAIR VALUE OF FINANCIAL INSTRUMENTS ACCOUNTING FOR LEASES INCOME TAXES BASIC AND DILUTED LOSS PER SHARE STOCK-BASED COMPENSATION RECENT ACCOUNTING PRONOUNCEMENTS Schedule of fair value measurement of assets and liabilities INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Tables) Schedule of changes to the investment in Imagion Schedule of debt discount OPTIONS AND WARRANTS (Tables) Summary of Company's stock option activity Exercise prices and weighted-average contractual lives of stock options outstanding Warrants issued at corresponding weighted average exercise price BASIS OF PRESENTATION (Details Narrative) Accumulated loss Working capital deficit Net loss SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Total fair value [Member] Quoted prices in active markets for identical assets [Member] (Level 1) [Member] Significant other observable inputs [Member] (Level 2) [Member] Significant unobservable inputs [Member] (Level 3) [Member] Investment in equity securities [Investments, Fair Value Disclosure] Related Party Transactions By Related Party Axis Plan Name Axis Imagion Biosystems, Inc., [Member] Common Stock [Member] Los Alamos National Security LLC [Member] Patent license agreement [Member] Proceeds from sale of assets held for sale Cash FDIC insured amount Sale of asset Proceeds from sale of asset description Impairment and adjustment of assets valuation Income Tax Examination, Likelihood of Unfavorable Settlement Issued and outstanding shares noncontrolling interest Weighted average number diluted shares Annual license fee Balance as of December 31, 2019 Change due to the sale of securities in investment Change in the fair value of securities Balance as of March 31, 2020 INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative) Imagion Biosystems, Inc., [Member] Trading price per share Common stock owned shares Issued and outstanding shares noncontrolling interest Fair value of investment Restricted shares related to prepaid notes interests (Loss) on fair value adjustment of investments EX-101.CAL 7 mhtx-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 8 mhtx-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 9 mhtx-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 10 R26.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
NOTES PAYABLE
Notes payable	$ 150,000
Less: Discounts on notes payable	(65,000)
Notes payable, net of discounts	$ 85,000	$ 78,000

XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2020	May 20, 2020
Document And Entity Information
Entity Registrant Name	MANHATTAN SCIENTIFICS INC
Entity Central Index Key	0001099132
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2020
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Common Stock Shares Outstanding		557,781,064
Entity Interactive Data Current	Yes

XML 12 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) - USD ($)	Total	Preferred Stock Series A [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Common Stock [Member]
Balance, shares at Dec. 31, 2018		49,999			533,781,064
Balance, shares at Dec. 31, 2018	$ (150,000)		$ 67,289,000	$ (67,973,000)	$ 534,000
Net Loss	$ (436,000)			$ (436,000)
Balance, shares at Mar. 31, 2019		49,999			533,781,064
Balance, shares at Mar. 31, 2019	$ (586,000)		$ 67,289,000	$ (68,409,000)	$ 534,000
Balance, shares at Dec. 31, 2019		49,999			557,781,064
Balance, shares at Dec. 31, 2019	$ (1,005,000)		$ 67,632,000	$ (69,195,000)	$ 558,000
Net Loss	$ (732,000)			$ (732,000)
Balance, shares at Mar. 31, 2020		49,999			557,781,064
Balance, shares at Mar. 31, 2020	$ (1,737,000)		$ 67,632,000	$ (69,927,000)	$ 558,000

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686

+ Details

XML 13 R22.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Total fair value [Member]
Investment in equity securities	$ 408,000	$ 1,045,000
Quoted prices in active markets for identical assets [Member] \| (Level 1) [Member]
Investment in equity securities	408,000	1,045,000
Significant other observable inputs [Member] \| (Level 2) [Member]
Investment in equity securities
Significant unobservable inputs [Member] \| (Level 3) [Member]
Investment in equity securities

XML 14 R9.htm IDEA: XBRL DOCUMENT

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS)

3 Months Ended

Mar. 31, 2020

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS)

NOTE 3 - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS)

During the three months ended March 31, 2020, the Company sold 4,000,000 shares of Imagion and received cash proceeds of $84,000.

Below is reconciliation for the changes to the investment in Imagion for the three months ended March 31, 2020:

Balance as of December 31, 2019	$	1,045,000
Change due to the sale of securities		(84,000	)
Change in the fair value of securities		(553,000	)
Balance as of March 31, 2020	$	408,000

ZIP 16 0001477932-20-002969-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-20-002969-xbrl.zip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end XML 17 R33.htm IDEA: XBRL DOCUMENT v3.20.1

COMMITMENTS AND CONTINGENCIES (Details Narrative)
3 Months Ended

Mar. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

Lease term, description The lease was able to be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary date of the lease

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of terms and conditions of option to terminate lessor's operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=119202524&loc=SL77919359-209981
+ Details

Name: us-gaap_LessorOperatingLeaseOptionToTerminate

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 18 R18.htm IDEA: XBRL DOCUMENT v3.20.1

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Tables)
3 Months Ended

Mar. 31, 2020

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Tables)

Schedule of changes to the investment in Imagion

Balance as of December 31, 2019

$

1,045,000

Change due to the sale of securities

(84,000

)

Change in the fair value of securities

(553,000

)

Balance as of March 31, 2020

$

408,000

X

- Definition
For all investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563
+ Details

Name: us-gaap_ScheduleOfUnrealizedLossOnInvestmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R14.htm IDEA: XBRL DOCUMENT v3.20.1

RELATED PARTY TRANSACTIONS
3 Months Ended

Mar. 31, 2020

RELATED PARTY TRANSACTIONS

NOTE 8 - RELATED PARTY TRANSACTIONS
As of March 31, 2020 and December 31, 2019, the Company had accrued expenses to related parties of approximately $667,000 and $583,750. During the three months ended March 31, 2020, the Company reclassified $1,276,000 from accrued expenses related party to accrued expenses after the Company reevaluated its related party transactions.

As of March 31, 2020, the amounts are due to the Company’s sole officer for compensation $188,000 and the chairman of the board for compensation of $439,000 and the members of the board of directors of $40,000.

As of March 31, 2020 and December 31, 2019, the Company had $100,000 and $100,000, respectively, of principal balance of notes payable due to a director of the Company. (See Note 4)

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.20.1

NOTES PAYABLE
3 Months Ended

Mar. 31, 2020

NOTES PAYABLE

NOTE 4 - NOTES PAYABLE
On October 17, 2019, The Company executed a secured note with a related party, a director of the Company, for $100,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.0257 per share with 2 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2020 was $4,600.

On October 17, 2019, The Company executed a secured note with an individual for $50,000. The secured note is due on October 17, 2022. The Company agreed that the note bears interest at 10% per annum, to be paid in advance in shares of Imagion Biosystems Limited common stock (IBX), calculated at $0.0257 per share with 1 million shares of IBX common stock. The amortization of debt discount for the three months ended March 31, 2020 was $2,400.

As of

March 31,

2020

Notes payable

$

150,000

Less: Discounts on notes payable

(65,000

)

Notes payable, net of discounts

$

85,000

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R32.htm IDEA: XBRL DOCUMENT v3.20.1

LICENSE AGREEMENT (Details Narrative)
3 Months Ended

Mar. 31, 2020

USD ($)

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative)

Minimum Royalty Payment $ 0

Royalty percentage on dental products 10.00%

License agreement term, description For a term of 17 years unless terminated sooner

Royalty percentage on other licensed products 5.00%

X

- References
No definition available.
+ Details

Name: mhtx_LicenseAgreementTermDescription

Namespace Prefix: mhtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_RoyaltyPercentageOnDentalProducts

Namespace Prefix: mhtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_RoyaltyPercentageOnOtherLicensedProducts

Namespace Prefix: mhtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccretionExpenseIncludingAssetRetirementObligationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 22 R15.htm IDEA: XBRL DOCUMENT v3.20.1

SUBSEQUENT EVENTS
3 Months Ended

Mar. 31, 2020

SUBSEQUENT EVENTS

NOTE 9 - SUBSEQUENT EVENTS
As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted.

In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2020 to the date these financial statements were issued, and there were no other material subsequent events to disclose in these financial statements, except as noted.

X

- Definition
Tabular disclosure of significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, losses resulting from fire or flood, losses on receivables, significant realized and unrealized gains and losses that result from changes in quoted market prices of securities, declines in market prices of inventory, changes in authorized or issued debt (SEC), significant foreign exchange rate changes, substantial loans to insiders or affiliates, significant long-term investments, and substantial dividends not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662
+ Details

Name: us-gaap_ScheduleOfSubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.20.1

OPTIONS AND WARRANTS
3 Months Ended

Mar. 31, 2020

OPTIONS AND WARRANTS

NOTE 5 - OPTIONS AND WARRANTS
A summary of the Company’s stock option activity and related information is as follows:

Number of Options

Exercise Price Per Share

Weighted Average Exercise Price

Number of Options Exercisable

Outstanding as of December 31, 2019

22,075,000

$ 0.07

$ .07

22,075,000

Granted

-

-

-

-

Exercised

-

-

-

-

Expired

-

-

-

-

Outstanding as of March 31, 2020

22,075,000

$ 0.07

$ 0.07

22,075,000

Exercise prices and weighted-average contractual lives of 22,075,000 stock options outstanding as of March 31, 2020 are as follows:

Options Outstanding

Options Exercisable

Exercise Price

Number Outstanding

Weighted Average Remaining Contractual Life

Number
Exercisable

$ 0.05

3,000,000

5.24

3,000,000

$ 0.06

6,000,000

4.62

6,000,000

$ 0.07

9,000,000

1.13

9,000,000

$ 0.08

575,000

0.68

575,000

$ 0.14

3,000,000

4.24

3,000,000

$ 0.02

500,000

4.25

500,000

The fair value for options granted were determined using the Black-Scholes option-pricing model.

Warrants:

The Company issued the following warrants at the corresponding weighted average exercise price as of March 31, 2020.

Number of Warrants

Exercise Price Per Share

Weighted Average Exercise Price

Number of Warrants Exercisable

Outstanding as of December 31, 2019

9,700,000

$ 0.07

$ 0.07

9,700,000

Granted

-

-

-

-

Exercised

-

-

-

-

Expired

(2,500,000 )

0.12

0.12

(2,500,000 )
Outstanding as of March 31, 2020

7,200,000

7,200,000

Grant date

Number of Warrants

Exercise Price

Contractual Life Remaining

Number of Shares Exercisable

April 2012

6,000,000

$ 0.05

0.6 years

6,000,000

July 2015

300,000

$ 0.05

0.2 years

300,000

August 2015

300,000

$ 0.05

0.3 years

300,000

September 2015

300,000

$ 0.05

0.4 years

300,000

October 2015

300,000

$ 0.05

0.5 years

300,000

7,200,000

7,200,000

The fair value for warrants granted were determined using the Black-Scholes option-pricing model.

X

- Definition
Tabular disclosure of share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R19.htm IDEA: XBRL DOCUMENT v3.20.1

NOTES PAYABLE (Tables)
3 Months Ended

Mar. 31, 2020

NOTES PAYABLE

Schedule of debt discount

Notes payable

$

150,000

Less: Discounts on notes payable

(65,000

)

Notes payable, net of discounts

$

85,000

X

- References
No definition available.
+ Details

Name: mhtx_ScheduleOfDebtDiscountTableTextBlock

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NotesPayableAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

EXCEL 25 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 26 R8.htm IDEA: XBRL DOCUMENT v3.20.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS
3 Months Ended

Mar. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION:

The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.

USE OF ESTIMATES:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

CASH CONCENTRATION:

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2020 and December 31, 2019, we had cash balances of $0 and $0 exceeding the federally insured limits.

PROPERTY AND EQUIPMENT:

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes.

INTANGIBLE ASSETS:

License Agreements

In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. At March 31, 2020 and December 31, 2019, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS:

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2020, the Company received $300,000 and reduced the due from the sale of assets. As of March 31, 2020, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds.

REVENUE RECOGNITION:

The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.



FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2019, consisted of the following:

Total fair value at March 31, 2020

Quoted prices in active markets for identical assets (Level 1)

Significant other observable inputs (Level 2)

Significant unobservable inputs (Level 3)

Investment in equity securities

$ 408,000

$ 408,000

$ -

$ -

Total fair value at December 31, 2019

Quoted prices in active markets for identical assets (Level 1)

Significant other observable inputs (Level 2)

Significant unobservable inputs (Level 3)

Investment in equity securities

$ 1,045,000

$ 1,045,000

$ -

$ -

Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2020 and December 31, 2019 because of the relative short term nature of these instruments.

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

As of March 31, 2020, the Company holds approximately 11% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss.



ACCOUNTING FOR LEASES

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements.

INCOME TAXES

The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.

Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

BASIC AND DILUTED LOSS PER SHARE

In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2020 and 2019, 31,697,917 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share as the effect of these shares on earnings per share would have been anti-dilutive.

STOCK BASED COMPENSATION

In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.

RECENT ACCOUNTING PRONOUNCEMENTS

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13. The implementation of this standard did not have any material impact on our consolidated financial statements.

The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements except “Fair Value measurements.”

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R27.htm IDEA: XBRL DOCUMENT v3.20.1

NOTES PAYABLE (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended

Oct. 17, 2019

Mar. 31, 2020

Mar. 31, 2019

Amortization of debt discount $ 7,000

Related Party [Member]

Secured note $ 100,000

Interest rate 10.00%

Debt due date Oct. 17, 2022

Shares issued in advance for debt 2,000,000

Price per share $ 0.0257

Amortization of debt discount 4,600

Individual [Member]

Secured note $ 50,000

Interest rate 10.00%

Debt due date Oct. 17, 2022

Shares issued in advance for debt 1,000,000

Amortization of debt discount $ 2,400

Price per share $ 0.0257

X

- References
No definition available.
+ Details

Name: mhtx_PricePerShares

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_PricesPerShares

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_SharesIssuedInAdvanceForDebt

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromSecuredNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mhtx_RelatedPartyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_IndividualMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R23.htm IDEA: XBRL DOCUMENT v3.20.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended

May 31, 2019

Mar. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2009

Proceeds from sale of assets held for sale $ 300,000 $ 300,000

Cash FDIC insured amount $ 250,000

Sale of asset $ 1,200,000

Proceeds from sale of asset description The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1.

Impairment and adjustment of assets valuation $ 1,200,000

Income Tax Examination, Likelihood of Unfavorable Settlement An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained

Common Stock [Member]

Weighted average number diluted shares 31,697,917 50,798,182

Imagion Biosystems, Inc., [Member]

Issued and outstanding shares noncontrolling interest 11.00% 31.00%

Los Alamos National Security LLC [Member] | Patent license agreement [Member]

Annual license fee $ 10,000

X

- References
No definition available.
+ Details

Name: mhtx_AnnualLicenseFee

Namespace Prefix: mhtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_IssuedAndOutstandingSharesNoncontrollingInterest

Namespace Prefix: mhtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: mhtx_ProceedsFromSaleOfAssetDescription

Namespace Prefix: mhtx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.
+ References
No definition available.
+ Details

Name: us-gaap_CashFDICInsuredAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 15
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=65877542&loc=d3e27249-109313

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319
+ Details

Name: us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow from the sale of other assets as part of operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfOtherAssets1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyHeldForSale

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mhtx_ImagionBiosystemsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mhtx_LosAlamosNationalSecurityLLCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=mhtx_PatentLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R4.htm IDEA: XBRL DOCUMENT v3.20.1

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Revenue

Operating costs:

General and administrative expenses 169,000 220,000

Research and development 3,000 1,000

Total operating costs and expenses 172,000 221,000

Loss from operations before other income and expenses (172,000) (221,000)

Other income and (expenses):

Loss on fair value adjustment of investments (553,000) (215,000)

Interest expense (7,000)

Total other income (expense) (560,000) (215,000)

NET LOSS $ (732,000) $ (436,000)

LOSS PER COMMON SHARE:

Weighted average number of common shares outstanding (Basic) 557,781,064 533,781,064

Basic loss per common share $ (0.00) $ (0.00)

Weighted average number of common shares outstanding (Diluted) 557,781,064 533,781,064

Diluted loss per common share $ (0.00) $ (0.00)

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareBasicAndDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of realized and unrealized gain (loss) on investment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27405-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(c),9(a))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingCostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 30 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 31 R17.htm IDEA: XBRL DOCUMENT v3.20.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables)
3 Months Ended

Mar. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

Schedule of fair value measurement of assets and liabilities

Total fair value at March 31, 2020

Quoted prices in active markets for identical assets (Level 1)

Significant other observable inputs (Level 2)

Significant unobservable inputs (Level 3)

Investment in equity securities

$

408,000

$

408,000

$

-

$

-

Total fair value at December 31, 2019

Quoted prices in active markets for identical assets (Level 1)

Significant other observable inputs (Level 2)

Significant unobservable inputs (Level 3)

Investment in equity securities

$

1,045,000

$

1,045,000

$

-

$

-

X

- References
No definition available.
+ Details

Name: mhtx_ScheduleOfFairValueMeasurementOfAssetsAndLiabilitiesTableTextBlock

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 32 R13.htm IDEA: XBRL DOCUMENT v3.20.1

COMMITMENTS AND CONTIGENCIES
3 Months Ended

Mar. 31, 2020

COMMITMENTS AND CONTIGENCIES

NOTE 7 - COMMITMENTS AND CONTIGENCIES
Legal matter contingencies

The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change.

Lease

The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. During the year ended December 31, 2019, the lease was assigned to a third party entity. The lease was able to be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary date of the lease. The Company adopted ASC 842 on January 1, 2019 and which had no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore is not required to be capitalized.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R30.htm IDEA: XBRL DOCUMENT v3.20.1

OPTIONS AND WARRANTS (Details 2)
3 Months Ended

Mar. 31, 2020

$ / shares

shares

Number of Options, Granted | shares

Number of Options, Exercised | shares

Exercise Price Per Share, Granted | $ / shares

Exercise Price Per Share, Exercised | $ / shares

Weighted Average Exercise Price, Granted | $ / shares

Weighted Average Exercise Price, Exercised | $ / shares

Weighted Average Exercise Price, Ending Balance | $ / shares $ 0.07

Number of Options Exercisable, Granted | shares

Number of Options Exercisable, Exercised | shares

Warrants [Member]

Number of Options, Outstanding Beginning Balance | shares 9,700,000

Number of Options, Expired | shares (2,500,000)

Number of Options, Outstanding Ending Balance | shares 7,200,000

Exercise Price Per Share, Beginning Balance | $ / shares $ 0.07

Exercise Price Per Share, Expired | $ / shares 0.12

Exercise Price Per Share, Ending Balance | $ / shares

Weighted Average Exercise Price, Beginning Balance | $ / shares 0.07

Weighted Average Exercise Price, Expired | $ / shares $ 0.12

Number of Options Exercisable,Outstanding Beginning Balance | shares 9,700,000

Number of Options Exercisable, Expired | shares (2,500,000)

Number of Options Exercisable,Outstanding Ending Balance | shares 7,200,000

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareBeginningBalances

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareEndingBalances

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareExercised

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareExpire

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsExercisableOutstandingBeginningBalances

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsExercisableOutstandingEndingBalances

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsExercisablesExpire

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsExpire

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsOutstandingBeginningBalances

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsOutstandingEndingBalances

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredNumber

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePriceBeginningBalances

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePriceEndingBalance

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePriceExercised

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePricesExpire

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=mhtx_WarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R34.htm IDEA: XBRL DOCUMENT v3.20.1

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended

Mar. 31, 2020

Dec. 31, 2019

Accrued expenses - related parties $ 667,000 $ 583,750

Accrued expenses 1,276,000

Notes payable due to related party 100,000 $ 100,000

Sole Officer [Member]

Due to related parties 188,000

Chairman [Member]

Due to related parties 439,000

Board of Director [Member]

Due to related parties $ 40,000

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_NotesPayableRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=mhtx_SoleOfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=mhtx_ChairmanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=mhtx_BoardOfDirectorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 R29.htm IDEA: XBRL DOCUMENT v3.20.1

OPTIONS AND WARRANTS (Details 1)
3 Months Ended

Mar. 31, 2020

$ / shares

shares

Number of Options Exercisable, Outstanding 7,200,000

Exercise Price 0.05 [Member]

Number of Options, Outstanding 3,000,000

Weighted Average Remaining Contractual Life 5 years 2 months 27 days

Weighted Average Exercise Price | $ / shares $ 0.05

Number of Options Exercisable, Outstanding 3,000,000

Exercise Price 0.06 [Member]

Number of Options, Outstanding 6,000,000

Weighted Average Remaining Contractual Life 4 years 7 months 13 days

Weighted Average Exercise Price | $ / shares $ 0.06

Number of Options Exercisable, Outstanding 6,000,000

Exercise Price 0.07 [Member]

Number of Options, Outstanding 9,000,000

Weighted Average Remaining Contractual Life 1 year 1 month 17 days

Weighted Average Exercise Price | $ / shares $ 0.07

Number of Options Exercisable, Outstanding 9,000,000

Exercise Price 0.08 [Member]

Number of Options, Outstanding 575,000

Weighted Average Remaining Contractual Life 8 months 5 days

Weighted Average Exercise Price | $ / shares $ 0.08

Number of Options Exercisable, Outstanding 575,000

Exercise Price 0.14 [Member]

Number of Options, Outstanding 3,000,000

Weighted Average Remaining Contractual Life 4 years 2 months 27 days

Weighted Average Exercise Price | $ / shares $ 0.14

Number of Options Exercisable, Outstanding 3,000,000

Exercise Price 0.02 [Member]

Number of Options, Outstanding 500,000

Weighted Average Remaining Contractual Life 4 years 2 months 30 days

Weighted Average Exercise Price | $ / shares $ 0.02

Number of Options Exercisable, Outstanding 500,000

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=mhtx_ExercisePriceRangeTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=mhtx_ExercisePriceRangeThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=mhtx_ExercisePriceRangeFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=mhtx_ExercisePriceRangeFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=mhtx_ExercisePriceRangeSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=mhtx_ExercisePriceRangeSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.20.1

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative) - Imagion Biosystems, Inc., [Member] - USD ($)
1 Months Ended 3 Months Ended

Mar. 25, 2020

Mar. 31, 2020

Dec. 31, 2019

Trading price per share $ 0.007

Common stock owned shares 56,516,508

Issued and outstanding shares noncontrolling interest 11.00% 31.00%

Fair value of investment $ 408,000

Restricted shares related to prepaid notes interests 1,000,000

(Loss) on fair value adjustment of investments $ 553,000

Descrpiton of equity method investment Shareholders will be offered two new shares for every five shares held at March 30, 2020. With new share, shareholders will receive a free attaching new option. New option will have an exercise price of 3 cents (Australian currency) and term of three years

Right to buy shares under equity method investment, shares 22,606,603

Right to buy shares under equity method investment, amount $ 13,813

Proceeds from sale of common stock $ 84,000

Sale of common stock 4,000,000

X

- References
No definition available.
+ Details

Name: mhtx_IssuedAndOutstandingSharesNoncontrollingInterest

Namespace Prefix: mhtx_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: mhtx_RestrictedSharesRelatedToIssuedPromissoryNotesInterest

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: mhtx_RightToBuySharesUnderEquityMethodInvestmentAmount

Namespace Prefix: mhtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_TradingPricePerShare

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of equity interests issued or issuable to acquire entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479
+ Details

Name: us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership.
+ References
No definition available.
+ Details

Name: us-gaap_EquityMethodInvestmentAdditionalInformation

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-12C.Column C.7)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14.Column E.2,3)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12.Column C.3,4)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 5
-Subparagraph (SX 210.12-13.Column C.6)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010
+ Details

Name: us-gaap_InvestmentOwnedAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Balance held at close of period in number of shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 50
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-12C.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 1
-Subparagraph (SX 210.12-12.Column B)
-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010
+ Details

Name: us-gaap_InvestmentOwnedBalanceShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mhtx_ImagionBiosystemsIncMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R2.htm IDEA: XBRL DOCUMENT v3.20.1

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Mar. 31, 2020

Dec. 31, 2019

Current assets:

Cash $ 241,000 $ 261,000

Prepaid expenses 18,000 13,000

Due from the sale of assets - current portion 300,000 300,000

Total current assets 559,000 574,000

Investment in equity securities 408,000 1,045,000

Property and equipment, net 8,000 4,000

Due from the sale of assets 600,000 600,000

Other assets 2,000 2,000

Total assets 1,577,000 2,225,000

Current liabilities:

Accounts payable and accrued expenses 1,504,000 1,510,250

Accrued expenses - related parties 667,000 583,750

Total current liabilities 2,171,000 2,094,000

Long-term liabilities:

Notes payable, net of discounts 85,000 78,000

Total long-term liabilities 85,000 78,000

Total liabilities 2,256,000 2,172,000

Commitments and Contingencies - Note 7

STOCKHOLDERS' EQUITY DEFICIT

Preferred Stock Value

Common, authorized 950,000,000 shares, 557,781,064 and 557,781,064 shares issued, and outstanding, respectively 558,000 558,000

Additional paid-in-capital 67,632,000 67,632,000

Accumulated deficit (69,927,000) (69,195,000)

Total stockholders' deficit (1,737,000) (1,005,000)

TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT 1,577,000 2,225,000

Class A Convertible Preferred Stock [Member]

STOCKHOLDERS' EQUITY DEFICIT

Preferred Stock Value

Class B Convertible Preferred Stock [Member]

STOCKHOLDERS' EQUITY DEFICIT

Preferred Stock Value

Class C Redeemable Convertible Preferred Stock [Member]

STOCKHOLDERS' EQUITY DEFICIT

Preferred Stock Value

Series D convertible preferred Stock [Member]

STOCKHOLDERS' EQUITY DEFICIT

Preferred Stock Value $ 1,058,000 $ 1,058,000

X

- References
No definition available.
+ Details

Name: mhtx_DueFromTheSaleOfAssets

Namespace Prefix: mhtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_DueFromRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.1(h))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Investments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of obligation due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(25))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(23))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(26))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 201.5-02(24))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_ClassAConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_ClassBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_ClassCRedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_SeriesDconvertiblepreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R6.htm IDEA: XBRL DOCUMENT v3.20.1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss $ (732,000) $ (436,000)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 1,000

Loss on fair value adjustment of investments 553,000 215,000

Amortization of debt discount 7,000

Changes in:

Prepaid expenses (5,000) (6,000)

Accounts payable and accrued expenses 77,000 117,000

Deposit for asset sale 10,000

Net cash used in operating activities (100,000) (99,000)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of fixed assets (4,000) (2,000)

Proceeds from sale of investments 84,000

Net cash provided by (used in) investing activities 80,000 (2,000)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from notes payable 50,000

Net cash provided by financing activities 50,000

NET DECREASE IN CASH (20,000) (51,000)

CASH, BEGINNING OF PERIOD 261,000 87,000

CASH, END OF PERIOD 241,000 36,000

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Interest paid

Income taxes paid

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.
+ References
No definition available.
+ Details

Name: us-gaap_AssetsFairValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
+ References
No definition available.
+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInDepositOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfInvestmentProjects

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R21.htm IDEA: XBRL DOCUMENT v3.20.1

BASIS OF PRESENTATION (Details Narrative) - USD ($)
3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

BASIS OF PRESENTATION (Details Narrative)

Accumulated loss $ (69,927,000) $ (69,195,000)

Working capital deficit (1,612,000)

Net loss $ (732,000) $ (436,000)

X

- References
No definition available.
+ Details

Name: mhtx_WorkingCapitalDeficit

Namespace Prefix: mhtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 41 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 86 265 1 false 35 0 false 4 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://mhtx.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://mhtx.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://mhtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfStockholdersEquityDeficitUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (Unaudited) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://mhtx.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 0000007 - Disclosure - BASIS OF PRESENTATION Sheet http://mhtx.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 7 false false R8.htm 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS Notes 8 false false R9.htm 0000009 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) Sheet http://mhtx.com/role/InvestmentInEquitySecuritiesImagionBiosystems INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) Notes 9 false false R10.htm 000010 - Disclosure - NOTES PAYABLE Notes http://mhtx.com/role/NotesPayable NOTES PAYABLE Notes 10 false false R11.htm 000011 - Disclosure - OPTIONS AND WARRANTS Sheet http://mhtx.com/role/OptionsAndWarrants OPTIONS AND WARRANTS Notes 11 false false R12.htm 000012 - Disclosure - LICENSE AGREEMENT Sheet http://mhtx.com/role/LicenseAgreement LICENSE AGREEMENT Notes 12 false false R13.htm 000013 - Disclosure - COMMITMENTS AND CONTIGENCIES Sheet http://mhtx.com/role/CommitmentsAndContigencies COMMITMENTS AND CONTIGENCIES Notes 13 false false R14.htm 000014 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://mhtx.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://mhtx.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies) Policies 16 false false R17.htm 000017 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Tables) Tables http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMatters 17 false false R18.htm 000018 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Tables) Sheet http://mhtx.com/role/InvestmentInEquitySecuritiesImagionBiosystemsTables INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Tables) Tables http://mhtx.com/role/InvestmentInEquitySecuritiesImagionBiosystems 18 false false R19.htm 000019 - Disclosure - NOTES PAYABLE (Tables) Notes http://mhtx.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://mhtx.com/role/NotesPayable 19 false false R20.htm 000020 - Disclosure - OPTIONS AND WARRANTS (Tables) Sheet http://mhtx.com/role/OptionsAndWarrantsTables OPTIONS AND WARRANTS (Tables) Tables http://mhtx.com/role/OptionsAndWarrants 20 false false R21.htm 000021 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://mhtx.com/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://mhtx.com/role/BasisOfPresentation 21 false false R22.htm 000022 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details) Details http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 22 false false R23.htm 000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Sheet http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) Details http://mhtx.com/role/SummaryOfSignificantAccountingPoliciesAndRelatedMattersTables 23 false false R24.htm 000024 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details) Sheet http://mhtx.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetails INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details) Details http://mhtx.com/role/InvestmentInEquitySecuritiesImagionBiosystemsTables 24 false false R25.htm 000025 - Disclosure - INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative) Sheet http://mhtx.com/role/InvestmentInEquitySecuritiesImagionBiosystemsDetailsNarrative INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative) Details http://mhtx.com/role/InvestmentInEquitySecuritiesImagionBiosystemsTables 25 false false R26.htm 000026 - Disclosure - NOTES PAYABLE (Details) Notes http://mhtx.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://mhtx.com/role/NotesPayableTables 26 false false R27.htm 000027 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://mhtx.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://mhtx.com/role/NotesPayableTables 27 false false R28.htm 000028 - Disclosure - OPTIONS AND WARRANTS (Details) Sheet http://mhtx.com/role/OptionsAndWarrantsDetails OPTIONS AND WARRANTS (Details) Details http://mhtx.com/role/OptionsAndWarrantsTables 28 false false R29.htm 000029 - Disclosure - OPTIONS AND WARRANTS (Details 1) Sheet http://mhtx.com/role/OptionsAndWarrantsDetails1 OPTIONS AND WARRANTS (Details 1) Details http://mhtx.com/role/OptionsAndWarrantsTables 29 false false R30.htm 000030 - Disclosure - OPTIONS AND WARRANTS (Details 2) Sheet http://mhtx.com/role/OptionsAndWarrantsDetails2 OPTIONS AND WARRANTS (Details 2) Details http://mhtx.com/role/OptionsAndWarrantsTables 30 false false R31.htm 000031 - Disclosure - OPTIONS AND WARRANTS (Details 3) Sheet http://mhtx.com/role/OptionsAndWarrantsDetails3 OPTIONS AND WARRANTS (Details 3) Details http://mhtx.com/role/OptionsAndWarrantsTables 31 false false R32.htm 000032 - Disclosure - LICENSE AGREEMENT (Details Narrative) Sheet http://mhtx.com/role/LicenseAgreementDetailsNarrative LICENSE AGREEMENT (Details Narrative) Details http://mhtx.com/role/LicenseAgreement 32 false false R33.htm 000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://mhtx.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details 33 false false R34.htm 000034 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://mhtx.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://mhtx.com/role/RelatedPartyTransactions 34 false false All Reports Book All Reports mhtx-20200331.xml mhtx-20200331.xsd mhtx-20200331_cal.xml mhtx-20200331_def.xml mhtx-20200331_lab.xml mhtx-20200331_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true true XML 42 R3.htm IDEA: XBRL DOCUMENT v3.20.1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Mar. 31, 2020

Dec. 31, 2019

Capital stock, shares par value $ .001 $ .001

Preferred stock, shares authorized 447,804 447,804

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, shares authorized 950,000,000 950,000,000

Common stock, shares issued 557,781,064 557,781,064

Common stock, shares outstanding 557,781,064 557,781,064

Series D convertible preferred Stock [Member]

Preferred stock, shares authorized 105,761 105,761

Preferred stock, shares issued 105,761 105,761

Preferred stock, shares outstanding 105,761 105,761

Class A Convertible Preferred Stock [Member]

Preferred stock, shares authorized 182,525 182,525

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Class B Convertible Preferred Stock [Member]

Preferred stock, shares authorized 250,000 250,000

Preferred stock, shares issued 49,999 49,999

Preferred stock, shares outstanding 49,999 49,999

Class C Redeemable Convertible Preferred Stock [Member]

Preferred stock, shares authorized 14,000 14,000

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_SeriesDconvertiblepreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_ClassAConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_ClassBConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=mhtx_ClassCRedeemableConvertiblePreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R24.htm IDEA: XBRL DOCUMENT v3.20.1

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details)
3 Months Ended

Mar. 31, 2020

USD ($)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details)

Balance as of December 31, 2019 $ 1,045,000

Change due to the sale of securities in investment (84,000)

Change in the fair value of securities (553,000)

Balance as of March 31, 2020 $ 408,000

X

- References
No definition available.
+ Details

Name: mhtx_BeginingBalance

Namespace Prefix: mhtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ChangeInTheFairValueOfSecurities

Namespace Prefix: mhtx_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_EndingBalance

Namespace Prefix: mhtx_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AcruedIncomeTaxesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in investment income that has been earned but not yet received in cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedInvestmentIncomeReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 44 R20.htm IDEA: XBRL DOCUMENT v3.20.1

OPTIONS AND WARRANTS (Tables)
3 Months Ended

Mar. 31, 2020

OPTIONS AND WARRANTS (Tables)

Summary of Company's stock option activity

Number of Options

Exercise Price Per Share

Weighted Average Exercise Price

Number of Options Exercisable

Outstanding as of December 31, 2019

22,075,000

$

0.07

$

.07

22,075,000

Granted

-

-

-

-

Exercised

-

-

-

-

Expired

-

-

-

-

Outstanding as of March 31, 2020

22,075,000

$

0.07

$

0.07

22,075,000

Exercise prices and weighted-average contractual lives of stock options outstanding

Options Outstanding

Options Exercisable

Exercise Price

Number Outstanding

Weighted Average Remaining Contractual Life

Number

Exercisable

$

0.05

3,000,000

5.24

3,000,000

$

0.06

6,000,000

4.62

6,000,000

$

0.07

9,000,000

1.13

9,000,000

$

0.08

575,000

0.68

575,000

$

0.14

3,000,000

4.24

3,000,000

$

0.02

500,000

4.25

500,000

Warrants issued at corresponding weighted average exercise price

Number of Warrants

Exercise Price Per Share

Weighted Average Exercise Price

Number of Warrants Exercisable

Outstanding as of December 31, 2019

9,700,000

$

0.07

$

0.07

9,700,000

Granted

-

-

-

-

Exercised

-

-

-

-

Expired

(2,500,000

)

0.12

0.12

(2,500,000

)

Outstanding as of March 31, 2020

7,200,000

7,200,000

Grant date

Number of Warrants

Exercise Price

Contractual Life Remaining

Number of Shares Exercisable

April 2012

6,000,000

$

0.05

0.6 years

6,000,000

July 2015

300,000

$

0.05

0.2 years

300,000

August 2015

300,000

$

0.05

0.3 years

300,000

September 2015

300,000

$

0.05

0.4 years

300,000

October 2015

300,000

$

0.05

0.5 years

300,000

7,200,000

7,200,000

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricesAndWeightedaverageContractualLivesOfStockOptionsOutstandingTableTextBlock

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WarrantsIssuedAtCorrespondingWeightedAverageExercisePriceTableTextBlock

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountsReceivableAdditionalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R7.htm IDEA: XBRL DOCUMENT v3.20.1

BASIS OF PRESENTATION
3 Months Ended

Mar. 31, 2020

BASIS OF PRESENTATION

NOTE 1 - BASIS OF PRESENTATION
The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2019, filed on April 14, 2020. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented.

Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements.

As of March 31, 2020, the Company has cumulative losses totaling $69,927,000 and negative working capital of $1,612,000. The Company incurred a net loss of $732,000 for the three months ended March 31, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Because of these conditions, the Company will require additional working capital to develop business operations. Management’s plans are to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations.

The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

X

- Definition
The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R28.htm IDEA: XBRL DOCUMENT v3.20.1

OPTIONS AND WARRANTS (Details)
3 Months Ended

Mar. 31, 2020

$ / shares

shares

OPTIONS AND WARRANTS

Number of Options, Outstanding Beginning Balance | shares 22,075,000

Number of Options, Granted | shares

Number of Options, Exercised | shares

Number of Options, Expired | shares

Number of Options, Outstanding Ending Balance | shares 22,075,000

Exercise Price Per Share

Exercise Price Per Share, Beginning Balance | $ / shares $ 0.07

Exercise Price Per Share, Granted | $ / shares

Exercise Price Per Share, Exercised | $ / shares

Exercise Price Per Share, Expired | $ / shares

Exercise Price Per Share, Ending Balance | $ / shares 0.07

Weighted Average Exercise Price

Weighted Average Exercise Price, Beginning Balance | $ / shares 0.07

Weighted Average Exercise Price, Granted | $ / shares

Weighted Average Exercise Price, Exercised | $ / shares

Weighted Average Exercise Price, Expired | $ / shares

Weighted Average Exercise Price, Ending Balance | $ / shares $ 0.07

Number of Options Exercisable

Number of Options Exercisable,Outstanding Beginning Balance | shares 22,075,000

Number of Options Exercisable, Granted | shares

Number of Options Exercisable, Exercised | shares

Number of Options Exercisable, Expired | shares

Number of Options Exercisable,Outstanding Ending Balance | shares 22,075,000

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareBeginningBalance

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareEndingBalance

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareExercised

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ExercisePricePerShareExpired

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsExercisableOutstandingBeginningBalance

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsExercisableOutstandingEndingBalance

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsOutstandingBeginningBalance

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_NumberOfOptionsOutstandingEndingBalance

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredExercisableNumber

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredNumber

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisableNumber

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePriceBeginningBalance

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePriceEndingBalance

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePriceExercised

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_WeightedAverageExercisePriceExpired

Namespace Prefix: mhtx_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LineOfCreditFacilityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(4)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 47 R16.htm IDEA: XBRL DOCUMENT v3.20.1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Policies)
3 Months Ended

Mar. 31, 2020

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS

BASIS OF CONSOLIDATION

The consolidated financial statements include the accounts of Manhattan Scientific, Inc., its wholly owned subsidiary Metallicum. All significant intercompany balances and transactions have been eliminated.

USE OF ESTIMATES
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amount of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. A significant estimate includes the carrying value of the Company’s patents, fair value of the Company’s common stock, assumptions used in calculating the value of stock options, depreciation and amortization.

CASH CONCENTRATION

The Company’s cash accounts are federally insured up to $250,000 for each financial institution we hold our accounts in. As of March 31, 2020 and December 31, 2019, we had cash balances of $0 and $0 exceeding the federally insured limits.

PROPERTY AND EQUIPMENT
Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes.

INTANGIBLE ASSETS
In 2009, the Company entered into a patent license agreement with Los Alamos National Security LLC for the exclusive use of certain technology relating to the manufacture and application of nanostructuring metals and alloys. At March 31, 2020 and December 31, 2019, the license agreements were fully amortized. Beginning in 2010, the Company was required to pay an annual license fee of $10,000 and may be required to pay royalties, as defined, to the licensors.

DUE FROM THE SALE OF ASSETS

Non-current assets are classified as held for sale if it is highly probably that they will be recovered primarily through sale rather than through continuing use.

Immediately before classification as held for sale, the assets are remeasured at the lower of their carrying amount and fair value less costs to sell. Any impairment loss on initial classification as held for sale and subsequent gains and losses on re-measurement are recognized in profit or loss. Gains are not recognized in excess of any cumulative impairment loss.

During the year ended December 31, 2019, the Company sold the assets held for sale that were presented on the balance sheet as of December 31, 2018. During the year ended December 31, 2018, the Company recorded impairment and adjusted the asset valuation to $1.2 million. The Company sold the assets for a total of $1.2 million of which $300,000 was received during the year ended December 31, 2019. The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1. During May 2020, the Company received $300,000 and reduced the due from the sale of assets. As of March 31, 2020, the Company evaluated the collectability and determined that no allowance is needed at this time due to the payment history with this third party and the subsequent receipt of funds.

REVENUE RECOGNITION
The Company recognizes revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which consists of five steps to evaluating contracts with customers for revenue recognition: (i) identify the contract with the customer; (ii) identity the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or as the entity satisfied a performance obligation.

Revenue recognition occurs at the time we satisfy a performance obligation to our customers, when control transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. We only record revenue when collectability is probable.

FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company recognized the fair value of financial instruments in accordance with FASB ASC 820, Fair Value Measurements and Disclosures, “Fair Value Measurements”, which provides a framework for measuring fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The standard also expands disclosures about instruments measured at fair value and establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:

Level 1 — Quoted prices for identical assets and liabilities in active markets;

Level 2 — Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and

Level 3 — Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

The Company designates cash equivalents (consisting of money market funds) and investments in securities of publicly traded companies as Level 1. The total amount of the Company’s investment classified as Level 3 is de minimis.

Our financial assets and liabilities carried at fair value measured on a recurring basis as of March 31, 2020 and December 31, 2019, consisted of the following:

Total fair value at March 31, 2020

Quoted prices in active markets for identical assets (Level 1)

Significant other observable inputs (Level 2)

Significant unobservable inputs (Level 3)

Investment in equity securities

$ 408,000

$ 408,000

$ -

$ -

Total fair value at December 31, 2019

Quoted prices in active markets for identical assets (Level 1)

Significant other observable inputs (Level 2)

Significant unobservable inputs (Level 3)

Investment in equity securities

$ 1,045,000

$ 1,045,000

$ -

$ -

Fair value of financial instruments: The carrying amounts of financial instruments, including cash and cash equivalents, short-term investments, accounts payable, accrued expenses and notes payables approximated fair value as of March 31, 2020 and December 31, 2019 because of the relative short term nature of these instruments.

During the year ended December 31, 2017, the Company elected fair value option for its investment in Imagion Biosystems, Inc. a Nevada company (“Imagion”) based on triggering event of dilution of ownership, which lead to the deconsolidation of Imagion. Investments in Imagion are measured at fair value as opposed to equity method based on ASC 825-10. The guidance allows entities to elect to measure certain financial assets and financial liabilities (as well as certain nonfinancial instruments that are similar to financial instruments) at fair value. Investments over which an investor has the ability to exercise significant influence are eligible for the fair value option as they represent recognized financial assets. When the fair value option is elected for an instrument, all subsequent changes in fair value for that instrument are reported in earnings.

As of March 31, 2020, the Company holds approximately 11% of the total issued and outstanding shares of Imagion and is reported under fair value method under ASC 320. Management determined that it was appropriate to carry its investment in Imagion at fair value because the investment is traded on the Australian stock exchange and has daily trading activity and is a better indicator of value. The investments are re-measured at the end of each quarter based on the trading price and converted from AUD to USD. Any change in the value is reported on the income statement as an unrealized gain or loss.

ACCOUNTING FOR LEASES
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) and subsequent amendments to the initial guidance: ASU 2017-13, ASU 2018-10, ASU 2018-11, ASU 2018-20 and ASU 2019-01 (collectively, Topic 842). Topic 842 requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company early adopted Topic ASC 842 using the effective date of January 1, 2019 as the date of our initial application of the standard. The Company used the new transition election to not restate comparative periods and elected the package of practical expedients upon adoption, which permits the Company to not reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. Consequently, financial information for the comparative periods will not be updated. Upon adoption, there was no material impact to the financial statements.

INCOME TAXES
The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s consolidated balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the consolidated statements of operations.

ASC 740-10 clarifies the accounting for uncertainty in income taxes recognized in an entity’s financial statements and prescribes a recognition threshold and measurement attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return.

Under ASC 740-10, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, ASC 740-10 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As a result of the implementation of ASC 740-10, the Company recognized no material adjustment in the liability for unrecognized income tax benefits.

BASIC AND DILUTED LOSS PER SHARE
In accordance with FASB ASC 260, “Earnings Per Share,” the basic loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Basic net loss per share excludes the dilutive effect of stock options or warrants and convertible notes. Diluted net earnings (loss) per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be issued upon exercise of common stock options and warrants. In periods where losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of March 31, 2020 and 2019, 31,697,917 and 50,798,182, respectively, dilutive shares were excluded from the calculation of diluted loss per common share as the effect of these shares on earnings per share would have been anti-dilutive.

STOCK-BASED COMPENSATION

In June 2018, FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718),Improvements to Nonemployee Share Based Payment Accounting. The amendments in this Update expand the scope of stock compensation to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance in this Update does not apply to transactions involving equity instruments granted to a lender or investor that provides financing to the issuer. The guidance is effective for fiscal years beginning after December 31, 2018 including interim periods within the fiscal year. The Company adopted with an effective date of January 1, 2019. Upon adoption, there was no material impact to the financial statements.

RECENT ACCOUNTING PRONOUNCEMENTS
In August 2018, the FASB issued ASU 2018-13, Disclosure Framework — Changes to the Disclosure Requirements for Fair Value Measurement, which removes, modifies, and adds certain disclosure requirements related to fair value measurements in ASC Topic 820. This guidance is effective for public companies in fiscal years beginning after December 15, 2019, with early adoption permitted. Effective January 1, 2020, we adopted ASU 2018-13. The implementation of this standard did not have any material impact on our consolidated financial statements.

The Company does not expect the adoption of recently issued accounting pronouncements to have a potential impact on the Company’s results of operations, financial position or cash flow.

The Company has evaluated all recent accounting pronouncements and none are expected to have a material impact on the condensed consolidated financial statements except “Fair Value measurements.”

X

- References
No definition available.
+ Details

Name: mhtx_CashConcentration

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_DueFromTheSaleOfAssetsPolicyTextBlock

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: mhtx_OperatingLeasesOfLesseeDisclosurePolicyTextBlock

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790
+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(f)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901
+ Details

Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R12.htm IDEA: XBRL DOCUMENT v3.20.1

LICENSE AGREEMENT
3 Months Ended

Mar. 31, 2020

LICENSE AGREEMENT

NOTE 6 - LICENSE AGREEMENT
On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products.

During the three months ended March 31, 2020, the Company received $0 as a minimum royalty payment.

X

- References
No definition available.
+ Details

Name: mhtx_LicenseAgreementTextBlock

Namespace Prefix: mhtx_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AgricultureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 49 R31.htm IDEA: XBRL DOCUMENT v3.20.1

OPTIONS AND WARRANTS (Details 3)
3 Months Ended

Mar. 31, 2020

$ / shares

shares

Number of Warrants, Outstanding Beginning Balance 7,200,000

Number of Shares Exercisable 7,200,000

April 2012 [Member]

Number of Warrants, Outstanding Beginning Balance 6,000,000

Number of Shares Exercisable 6,000,000

Weighted average Exercise Price, Beginning Balance | $ / shares $ 0.05

Contractual Life Remaining 7 months 6 days

July 2015 [Member]

Number of Warrants, Outstanding Beginning Balance 300,000

Number of Shares Exercisable 300,000

Weighted average Exercise Price, Beginning Balance | $ / shares $ 0.05

Contractual Life Remaining 2 months 12 days

August 2015 [Member]

Number of Warrants, Outstanding Beginning Balance 300,000

Number of Shares Exercisable 300,000

Weighted average Exercise Price, Beginning Balance | $ / shares $ 0.05

Contractual Life Remaining 3 months 18 days

September 2015 [Member]

Number of Warrants, Outstanding Beginning Balance 300,000

Number of Shares Exercisable 300,000

Weighted average Exercise Price, Beginning Balance | $ / shares $ 0.05

Contractual Life Remaining 4 months 24 days

October 2015 [Member]

Number of Warrants, Outstanding Beginning Balance 300,000

Number of Shares Exercisable 300,000

Weighted average Exercise Price, Beginning Balance | $ / shares $ 0.05

Contractual Life Remaining 5 months 30 days

X

- References
No definition available.
+ Details

Name: mhtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber

Namespace Prefix: mhtx_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AwardTypeAxis=mhtx_April2012Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=mhtx_July2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=mhtx_August2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=mhtx_September2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=mhtx_October2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

COMMITMENTS AND CONTINGENCIES (Details Narrative)	3 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative)	Mar. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS
Lease term, description	The lease was able to be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary date of the lease

RELATED PARTY TRANSACTIONS	3 Months Ended
RELATED PARTY TRANSACTIONS	Mar. 31, 2020
RELATED PARTY TRANSACTIONS
NOTE 8 - RELATED PARTY TRANSACTIONS	As of March 31, 2020 and December 31, 2019, the Company had accrued expenses to related parties of approximately $667,000 and $583,750. During the three months ended March 31, 2020, the Company reclassified $1,276,000 from accrued expenses related party to accrued expenses after the Company reevaluated its related party transactions. As of March 31, 2020, the amounts are due to the Company’s sole officer for compensation $188,000 and the chairman of the board for compensation of $439,000 and the members of the board of directors of $40,000. As of March 31, 2020 and December 31, 2019, the Company had $100,000 and $100,000, respectively, of principal balance of notes payable due to a director of the Company. (See Note 4)

LICENSE AGREEMENT (Details Narrative)	3 Months Ended
LICENSE AGREEMENT (Details Narrative)	Mar. 31, 2020 USD ($)
INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative)
Minimum Royalty Payment	$ 0
Royalty percentage on dental products	10.00%
License agreement term, description	For a term of 17 years unless terminated sooner
Royalty percentage on other licensed products	5.00%

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Mar. 31, 2020
SUBSEQUENT EVENTS
NOTE 9 - SUBSEQUENT EVENTS	As of the filing date, the Coronavirus (“COVID-19”) has caused significant volatility in global markets, including the market price of our securities. The demand for our products and services has decreased and the ability of our customers to make payments for the products and services they purchased has been negatively impacted. In accordance with ASC 855-10, the Company has analyzed its operations subsequent to March 31, 2020 to the date these financial statements were issued, and there were no other material subsequent events to disclose in these financial statements, except as noted.

NOTES PAYABLE (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Oct. 17, 2019	Mar. 31, 2020	Mar. 31, 2019
Amortization of debt discount		$ 7,000
Related Party [Member]
Secured note	$ 100,000
Interest rate	10.00%
Debt due date	Oct. 17, 2022
Shares issued in advance for debt	2,000,000
Price per share	$ 0.0257
Amortization of debt discount		4,600
Individual [Member]
Secured note	$ 50,000
Interest rate	10.00%
Debt due date	Oct. 17, 2022
Shares issued in advance for debt	1,000,000
Amortization of debt discount		$ 2,400
Price per share	$ 0.0257

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND RELATED MATTERS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	May 31, 2019	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2009
Proceeds from sale of assets held for sale	$ 300,000		$ 300,000
Cash FDIC insured amount		$ 250,000
Sale of asset				$ 1,200,000
Proceeds from sale of asset description		The remaining $900,000 will be collected during the next three years in equal increments on the anniversary date of the agreement, May 1.
Impairment and adjustment of assets valuation				$ 1,200,000
Income Tax Examination, Likelihood of Unfavorable Settlement		An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained
Common Stock [Member]
Weighted average number diluted shares		31,697,917	50,798,182
Imagion Biosystems, Inc., [Member]
Issued and outstanding shares noncontrolling interest		11.00%	31.00%
Los Alamos National Security LLC [Member] \| Patent license agreement [Member]
Annual license fee					$ 10,000

COMMITMENTS AND CONTIGENCIES	3 Months Ended
COMMITMENTS AND CONTIGENCIES	Mar. 31, 2020
COMMITMENTS AND CONTIGENCIES
NOTE 7 - COMMITMENTS AND CONTIGENCIES	Legal matter contingencies The Company believes, based on current knowledge and after consultation with counsel, that it is not currently party to any material pending proceedings, individually or in the aggregate, the resolution of which would have a material effect on the Company. Provisions for losses are established in accordance with ASC 450, “Contingencies” when warranted. Once established, such provisions are adjusted when there is more information available of when an event occurs requiring a change. Lease The Company leases a facility with terms of month to month for its headquarters and had a lease on a facility through April 2021. During the year ended December 31, 2019, the lease was assigned to a third party entity. The lease was able to be cancelled at any time with three months written notice before April 2020 and 2021, the anniversary date of the lease. The Company adopted ASC 842 on January 1, 2019 and which had no impact on the financial statements as under the practical expedient the leases consist of terms less than one year, and therefore is not required to be capitalized.

OPTIONS AND WARRANTS (Details 2)	3 Months Ended
OPTIONS AND WARRANTS (Details 2)	Mar. 31, 2020 $ / shares shares
Number of Options, Granted \| shares
Number of Options, Exercised \| shares
Exercise Price Per Share, Granted \| $ / shares
Exercise Price Per Share, Exercised \| $ / shares
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 0.07
Number of Options Exercisable, Granted \| shares
Number of Options Exercisable, Exercised \| shares
Warrants [Member]
Number of Options, Outstanding Beginning Balance \| shares	9,700,000
Number of Options, Expired \| shares	(2,500,000)
Number of Options, Outstanding Ending Balance \| shares	7,200,000
Exercise Price Per Share, Beginning Balance \| $ / shares	$ 0.07
Exercise Price Per Share, Expired \| $ / shares	0.12
Exercise Price Per Share, Ending Balance \| $ / shares
Weighted Average Exercise Price, Beginning Balance \| $ / shares	0.07
Weighted Average Exercise Price, Expired \| $ / shares	$ 0.12
Number of Options Exercisable,Outstanding Beginning Balance \| shares	9,700,000
Number of Options Exercisable, Expired \| shares	(2,500,000)
Number of Options Exercisable,Outstanding Ending Balance \| shares	7,200,000

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Accrued expenses - related parties	$ 667,000	$ 583,750
Accrued expenses	1,276,000
Notes payable due to related party	100,000	$ 100,000
Sole Officer [Member]
Due to related parties	188,000
Chairman [Member]
Due to related parties	439,000
Board of Director [Member]
Due to related parties	$ 40,000

OPTIONS AND WARRANTS (Details 1)	3 Months Ended
OPTIONS AND WARRANTS (Details 1)	Mar. 31, 2020 $ / shares shares
Number of Options Exercisable, Outstanding	7,200,000
Exercise Price 0.05 [Member]
Number of Options, Outstanding	3,000,000
Weighted Average Remaining Contractual Life	5 years 2 months 27 days
Weighted Average Exercise Price \| $ / shares	$ 0.05
Number of Options Exercisable, Outstanding	3,000,000
Exercise Price 0.06 [Member]
Number of Options, Outstanding	6,000,000
Weighted Average Remaining Contractual Life	4 years 7 months 13 days
Weighted Average Exercise Price \| $ / shares	$ 0.06
Number of Options Exercisable, Outstanding	6,000,000
Exercise Price 0.07 [Member]
Number of Options, Outstanding	9,000,000
Weighted Average Remaining Contractual Life	1 year 1 month 17 days
Weighted Average Exercise Price \| $ / shares	$ 0.07
Number of Options Exercisable, Outstanding	9,000,000
Exercise Price 0.08 [Member]
Number of Options, Outstanding	575,000
Weighted Average Remaining Contractual Life	8 months 5 days
Weighted Average Exercise Price \| $ / shares	$ 0.08
Number of Options Exercisable, Outstanding	575,000
Exercise Price 0.14 [Member]
Number of Options, Outstanding	3,000,000
Weighted Average Remaining Contractual Life	4 years 2 months 27 days
Weighted Average Exercise Price \| $ / shares	$ 0.14
Number of Options Exercisable, Outstanding	3,000,000
Exercise Price 0.02 [Member]
Number of Options, Outstanding	500,000
Weighted Average Remaining Contractual Life	4 years 2 months 30 days
Weighted Average Exercise Price \| $ / shares	$ 0.02
Number of Options Exercisable, Outstanding	500,000

INVESTMENT IN EQUITY SECURITIES (IMAGION BIOSYSTEMS) (Details Narrative) - Imagion Biosystems, Inc., [Member] - USD ($)	1 Months Ended	3 Months Ended
	Mar. 25, 2020	Mar. 31, 2020	Dec. 31, 2019
Trading price per share		$ 0.007
Common stock owned shares		56,516,508
Issued and outstanding shares noncontrolling interest		11.00%	31.00%
Fair value of investment		$ 408,000
Restricted shares related to prepaid notes interests		1,000,000
(Loss) on fair value adjustment of investments		$ 553,000
Descrpiton of equity method investment	Shareholders will be offered two new shares for every five shares held at March 30, 2020. With new share, shareholders will receive a free attaching new option. New option will have an exercise price of 3 cents (Australian currency) and term of three years
Right to buy shares under equity method investment, shares		22,606,603
Right to buy shares under equity method investment, amount		$ 13,813
Proceeds from sale of common stock		$ 84,000
Sale of common stock		4,000,000

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 241,000	$ 261,000
Prepaid expenses	18,000	13,000
Due from the sale of assets - current portion	300,000	300,000
Total current assets	559,000	574,000
Investment in equity securities	408,000	1,045,000
Property and equipment, net	8,000	4,000
Due from the sale of assets	600,000	600,000
Other assets	2,000	2,000
Total assets	1,577,000	2,225,000
Current liabilities:
Accounts payable and accrued expenses	1,504,000	1,510,250
Accrued expenses - related parties	667,000	583,750
Total current liabilities	2,171,000	2,094,000
Long-term liabilities:
Notes payable, net of discounts	85,000	78,000
Total long-term liabilities	85,000	78,000
Total liabilities	2,256,000	2,172,000
Commitments and Contingencies - Note 7
STOCKHOLDERS' EQUITY DEFICIT
Preferred Stock Value
Common, authorized 950,000,000 shares, 557,781,064 and 557,781,064 shares issued, and outstanding, respectively	558,000	558,000
Additional paid-in-capital	67,632,000	67,632,000
Accumulated deficit	(69,927,000)	(69,195,000)
Total stockholders' deficit	(1,737,000)	(1,005,000)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT	1,577,000	2,225,000
Class A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY DEFICIT
Preferred Stock Value
Class B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY DEFICIT
Preferred Stock Value
Class C Redeemable Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY DEFICIT
Preferred Stock Value
Series D convertible preferred Stock [Member]
STOCKHOLDERS' EQUITY DEFICIT
Preferred Stock Value	$ 1,058,000	$ 1,058,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (732,000)	$ (436,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,000
Loss on fair value adjustment of investments	553,000	215,000
Amortization of debt discount	7,000
Changes in:
Prepaid expenses	(5,000)	(6,000)
Accounts payable and accrued expenses	77,000	117,000
Deposit for asset sale		10,000
Net cash used in operating activities	(100,000)	(99,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(4,000)	(2,000)
Proceeds from sale of investments	84,000
Net cash provided by (used in) investing activities	80,000	(2,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from notes payable		50,000
Net cash provided by financing activities		50,000
NET DECREASE IN CASH	(20,000)	(51,000)
CASH, BEGINNING OF PERIOD	261,000	87,000
CASH, END OF PERIOD	241,000	36,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid
Income taxes paid

BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended
BASIS OF PRESENTATION (Details Narrative) - USD ($)	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
BASIS OF PRESENTATION (Details Narrative)
Accumulated loss	$ (69,927,000)		$ (69,195,000)
Working capital deficit	(1,612,000)
Net loss	$ (732,000)	$ (436,000)

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Capital stock, shares par value	$ .001	$ .001
Preferred stock, shares authorized	447,804	447,804
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	950,000,000	950,000,000
Common stock, shares issued	557,781,064	557,781,064
Common stock, shares outstanding	557,781,064	557,781,064
Series D convertible preferred Stock [Member]
Preferred stock, shares authorized	105,761	105,761
Preferred stock, shares issued	105,761	105,761
Preferred stock, shares outstanding	105,761	105,761
Class A Convertible Preferred Stock [Member]
Preferred stock, shares authorized	182,525	182,525
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Class B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	250,000	250,000
Preferred stock, shares issued	49,999	49,999
Preferred stock, shares outstanding	49,999	49,999
Class C Redeemable Convertible Preferred Stock [Member]
Preferred stock, shares authorized	14,000	14,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Mar. 31, 2020
BASIS OF PRESENTATION
NOTE 1 - BASIS OF PRESENTATION	The foregoing unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Regulation S-X as promulgated by the Securities and Exchange Commission (“SEC”). Accordingly, these financial statements do not include all of the disclosures required by generally accepted accounting principles in the United States of America for complete financial statements. These unaudited interim financial statements should be read in conjunction with the audited financial statements and the notes thereto included on Form 10-K for the year ended December 31, 2019, filed on April 14, 2020. In the opinion of management, the unaudited interim financial statements furnished herein include all adjustments, all of which are of a normal recurring nature, necessary for a fair statement of the results for the interim period presented. Operating results for the three-month period ended March 31, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020. The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles in the U.S. for complete financial statements. As of March 31, 2020, the Company has cumulative losses totaling $69,927,000 and negative working capital of $1,612,000. The Company incurred a net loss of $732,000 for the three months ended March 31, 2020. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Because of these conditions, the Company will require additional working capital to develop business operations. Management’s plans are to raise additional working capital through the continued licensing of its technology as well as to generate revenues for other services. There are no assurances that the Company will be able to achieve the level of revenues adequate to generate sufficient cash flow from operations to support the Company’s working capital requirements. To the extent that funds generated are insufficient, the Company will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on terms acceptable to the Company. If adequate working capital is not available, the Company may not continue its operations. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

OPTIONS AND WARRANTS (Details)	3 Months Ended
OPTIONS AND WARRANTS (Details)	Mar. 31, 2020 $ / shares shares
OPTIONS AND WARRANTS
Number of Options, Outstanding Beginning Balance \| shares	22,075,000
Number of Options, Granted \| shares
Number of Options, Exercised \| shares
Number of Options, Expired \| shares
Number of Options, Outstanding Ending Balance \| shares	22,075,000
Exercise Price Per Share
Exercise Price Per Share, Beginning Balance \| $ / shares	$ 0.07
Exercise Price Per Share, Granted \| $ / shares
Exercise Price Per Share, Exercised \| $ / shares
Exercise Price Per Share, Expired \| $ / shares
Exercise Price Per Share, Ending Balance \| $ / shares	0.07
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance \| $ / shares	0.07
Weighted Average Exercise Price, Granted \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 0.07
Number of Options Exercisable
Number of Options Exercisable,Outstanding Beginning Balance \| shares	22,075,000
Number of Options Exercisable, Granted \| shares
Number of Options Exercisable, Exercised \| shares
Number of Options Exercisable, Expired \| shares
Number of Options Exercisable,Outstanding Ending Balance \| shares	22,075,000

LICENSE AGREEMENT	3 Months Ended
LICENSE AGREEMENT	Mar. 31, 2020
LICENSE AGREEMENT
NOTE 6 - LICENSE AGREEMENT	On May 1, 2019, the Company, entered into an agreement with a non-affiliated third party (“Third Party”), providing for an exclusive license by the Company of its ECAP technology to the Third Party for a term of 17 years unless terminated sooner, a sublicense by the Company to the Third Party of its rights under that certain Exclusive Field-of-Use Patent License Agreement dated January 5, 2009 entered with The Los Alamos National Laboratory for a term until the expiration of the last valid claim to expire of the patents pursuant to such agreement and the sale by the Company of ECAP-C machines to the Third party. As part of the above license agreements, the Company will receive royalty payments, including minimum payments, based on a percentage of the Third Party’s sales. Royalties will be 10% on gross sales of licensed dental products and average of 5% on all other sales of licensed products. During the three months ended March 31, 2020, the Company received $0 as a minimum royalty payment.

OPTIONS AND WARRANTS (Details 3)	3 Months Ended
OPTIONS AND WARRANTS (Details 3)	Mar. 31, 2020 $ / shares shares
Number of Warrants, Outstanding Beginning Balance	7,200,000
Number of Shares Exercisable	7,200,000
April 2012 [Member]
Number of Warrants, Outstanding Beginning Balance	6,000,000
Number of Shares Exercisable	6,000,000
Weighted average Exercise Price, Beginning Balance \| $ / shares	$ 0.05
Contractual Life Remaining	7 months 6 days
July 2015 [Member]
Number of Warrants, Outstanding Beginning Balance	300,000
Number of Shares Exercisable	300,000
Weighted average Exercise Price, Beginning Balance \| $ / shares	$ 0.05
Contractual Life Remaining	2 months 12 days
August 2015 [Member]
Number of Warrants, Outstanding Beginning Balance	300,000
Number of Shares Exercisable	300,000
Weighted average Exercise Price, Beginning Balance \| $ / shares	$ 0.05
Contractual Life Remaining	3 months 18 days
September 2015 [Member]
Number of Warrants, Outstanding Beginning Balance	300,000
Number of Shares Exercisable	300,000
Weighted average Exercise Price, Beginning Balance \| $ / shares	$ 0.05
Contractual Life Remaining	4 months 24 days
October 2015 [Member]
Number of Warrants, Outstanding Beginning Balance	300,000
Number of Shares Exercisable	300,000
Weighted average Exercise Price, Beginning Balance \| $ / shares	$ 0.05
Contractual Life Remaining	5 months 30 days